WO1998032753A1 - THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY - Google Patents

THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Download PDF

Info

Publication number
WO1998032753A1
WO1998032753A1 PCT/US1998/001317 US9801317W WO9832753A1 WO 1998032753 A1 WO1998032753 A1 WO 1998032753A1 US 9801317 W US9801317 W US 9801317W WO 9832753 A1 WO9832753 A1 WO 9832753A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
phenyl
thiazol
amino
benzenesulfonamide
Prior art date
Application number
PCT/US1998/001317
Other languages
French (fr)
Inventor
Robert J. Mathvink
Emma R. Parmee
Samuel Tolman
Ann E. Weber
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705041.3A external-priority patent/GB9705041D0/en
Priority to EP98903677A priority Critical patent/EP0968209A1/en
Priority to EA199900692A priority patent/EA199900692A1/en
Priority to EEP199900328A priority patent/EE9900328A/en
Priority to JP53214898A priority patent/JP2001509166A/en
Priority to CA002278739A priority patent/CA2278739A1/en
Priority to PL98334833A priority patent/PL334833A1/en
Priority to HU0002053A priority patent/HUP0002053A3/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to IL13113098A priority patent/IL131130A0/en
Priority to BR9807096-7A priority patent/BR9807096A/en
Priority to SK1000-99A priority patent/SK100099A3/en
Priority to AU60384/98A priority patent/AU728812B2/en
Publication of WO1998032753A1 publication Critical patent/WO1998032753A1/en
Priority to IS5131A priority patent/IS5131A/en
Priority to NO993646A priority patent/NO993646L/en
Priority to BG103686A priority patent/BG103686A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • ⁇ -Adrenoceptors have been subclassified as ⁇ l and ⁇ 2 since 1967. Increased heart rate is the primary consequence of ⁇ l -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from ⁇ 2 stimulation.
  • Adipocyte lipolysis was initially thought to be solely a ⁇ l -mediated process. However, more recent results indicate that the receptor mediating lipolysis is atypical in nature. These atypical receptors, later called ⁇ 3-adrenoceptors, are found on the cell surface of both white and brown adipocytes where their stimulation promotes both lipolysis (breakdown of fat) and energy expenditure.
  • a major drawback in treatment of chronic diseases with ⁇ 3 agonists is the potential for stimulation of other ⁇ -receptors and subsequent side effects.
  • the most likely of these include muscle tremor ( ⁇ 2) and increased heart rate ( ⁇ l).
  • ⁇ 2 muscle tremor
  • ⁇ l increased heart rate
  • these phenylethanolamine derivatives do possess some ⁇ 3 selectivity, side effects of this type have been observed in human volunteers. It is reasonable to expect that these side effects resulted from partial ⁇ l and/or ⁇ 2 agonism.
  • the instant invention is concerned with thiazole substituted benzenesulfonamides which are useful as antiobesity and antidiabetic compounds.
  • a still further object is to describe processes for the preparation of such compounds.
  • Another object is to describe methods and compositions which use the compounds as the active ingredient thereof. Further objects will become apparent from reading the following description.
  • the present invention provides compounds having the formula I:
  • X is (1) a bond
  • C1-C3 alkylene wherein said alkylene contains an oxygen, optionally substituted with 1 or 2 groups selected from methyl and halogen; m is 0 to 5; A is (1) phenyl, (2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
  • Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 groups selected from
  • R4 is (1) H, or
  • X is (1) a bond
  • Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 halogens
  • R is (1) Cl-Cio alkyl
  • A is selected from phenyl, naphthyl, a 5 or 6- membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygenk sulfur and nitrogen fused to a benzene ring, and a 5 or 6- membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.
  • A is selected from phenyl, naphthyl, thienyl, pyridinyl, benzothienyl, quinolinyl, indolyl, and benzofuranyl.
  • A is (1) phenyl
  • Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 halogens
  • R3 is (1) Cl-ClO alkyl; and Q is (1) 0; or a pharmaceutically acceptable salt thereof.
  • X is (1) a bond, (2) CH 2 ,
  • A is (1) phenyl, (2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
  • Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 halogens; (2) halogen,
  • R is (1) hydrogen
  • Q is (1) O; and either the benzenesulfonamide moiety or X (or A, if X is a bond) is attached to the C2 of the thiazole ring, and the other to the C4 positions of the thiazole ring; or a pharmaceutically acceptable salt thereof.
  • Representative antiobesity and antidiabetic compounds of the present invention include the following: l. N-[4-[2-[[.2-hydroxy-2-(3- ⁇ yridinyl)ethyl]aminolethyl] ⁇ henyll-4-[4-(2- naphthylmethyl)thiazol-2-yl]benzenesulfonamide; 2. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
  • the compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in structural Formula I. Additional asymmetric centers may be present on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof, be included within the ambit of the instant invention.
  • the asymmetric center represented by the asterisk in Formula I it has been found that the compound in which the hydroxy substituent is above the plane of the structure, as seen in Formula Ic, is more active and thus more preferred over the compound in which the hydroxy substituent is below the plane of the structure.
  • the following stereospecific structure represents the preferred stereoisomers of the instant invention:
  • the thiazolyl moiety is numbered as follows:
  • Alkylene means -(CH2) ⁇ - where p is the designated carbon number; one or two of the hydrogen may be optionally replaced by methyl or halogen. Where the optionally substituted alkylene contains an oxygen, the oxygen may be at either end of the alkylene chain, or it may be embedded within the chain. Examples include OCH2, CH20, CH2OCH2, C(CH3)2 ⁇ , etc.
  • alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration.
  • exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
  • alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.
  • halogen is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.
  • a benzene ring fused to a C5-C10 carbocyclic ring includes naphthyl, tetrahydronaphthyl, indanyl and indenyl.
  • a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5-C10 carbocyclic ring includes benzene fused to a heterocyclic ring as well as a non-aromatic carbocyclic ring fused to a heterocyclic ring.
  • the carbocyclic ring preferably is C5-C7.
  • a 5 and 6-membered heterocyclic ring is intended to include aromatic and unsaturated non-aromatic heterocycles; and where the heterocycle is part of a fused ring, at least one of the rings is aromatic.
  • Examples of a 5 or 6- membered ring include pyridyl, pyrimidinyl, pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, oxazolyl, imidazolidinyl, pyrazolyl, isoxazolyl.
  • Examples of a benzene ring fused to a 5 or 6-membered heterocyclic ring include benzothiadiazolyl, indolyl, indolinyl, benzodioxolyl, benzodioxanyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazinyl, benzisoxazolyl, benzothiazolyl, 2,3-dihydrobenzofuranyl, quinolinyl, benzotriazolyl, benzoxazolyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl.
  • Examples of a 5 or 6-membered heterocyclic ring fused to a non-aromatic carbocyclic ring include tetrahydrobenzothiazolyl, 5,6,7,8-tetrahydroquinolinyl, 2,3- cyclopentenopyridyl, 4,5,6,7-tetrahydroindolyl, 5,6,7,8- tetrahydroisoquinolyl, 5,6,7, 8-tetrahydroquinoxalinyl.
  • composition as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • prodrugs are derivatives of compounds of Formula I that are transformed in vivo to the active drug molecule; prodrugs include derivatives of free hydroxy, amino or carboxylic groups such as esters, ethers, amides, carbonates, carbamates, and N-alkyl derivatives.
  • prodrugs of compounds of Formula I include: (a) derivation of the secondary amine such as N-alkylation (methyl, ethyl, isopropyl and 2- methoxy ethyl), and N-acylation (1-pyrrolidinylacetyl, 4- morpholinylacetyl, (l-acetoxy)ethoxycarbonyl, and dimethylaminoacetyl); (b) derivation of the secondary hydroxy such as O-alkylation (ethyl) and O-acylation (acetyl, t-butoxycarbonyl, benzoyl, cyclopropylcarbonyl); and (c) the vicinally positioned secondary amine and secondary hydroxy taken together form a group of the formula
  • U and V are independently a bond, carbonyl, methylene, CH(OH) or C(OH)(CH3).
  • Prodrugs of the above-described types may be readily prepared from compounds of Formula I using methods well know to persons skilled in the art.
  • NR 2 R 2 may represent NH2, NHCH3, N(CH3)CH2CH3, and the like.
  • the compounds (I) of the present invention can be prepared as described in the following schemes. Thiazoles la, lb and Ic are prepared via the Hantzsch thiazole synthesis (Sainsbury, M. In “Rodd's Chemistry of Carbon Compounds", Coffey, S., Ausell, M. F., Eds.; Elsevier: Amsterdam, 1986; Vol. IV C, 399-455) from the appropriate thioamide and 2-halocarbonyl derivative.
  • the protected aniline derivative 5 (Fisher, et. al, US 5,561,142, Oct. 1, 1996) is treated with sulfonyl chloride 4, and a base such as pyridine in an anhydrous solvent such as dichloromethane or chloroform for 0.5 to 24 hours at temperatures of -20 to 50°C, preferably 0°C, followed by removal of the protecting group with, in the case of a tert-butylcarbamate, acid such as trifluoroacetic acid or methanolic hydrogen chloride, provides the thiazole la.
  • a base such as pyridine
  • an anhydrous solvent such as dichloromethane or chloroform
  • the chloroketones 2 are commercially available, known in the literature, or readily prepared by methods commonly known to those skilled in the art. Conveniently, the corresponding acid chloride 6 is treated with diazomethane followed by hydrogen chloride to provide chloroketone 2, as illustrated in Scheme 2.
  • Nitrile 7 (Fisher, et. al, US 5,561,142, Oct. 1, 1996) is converted to the corresponding thiamide by treatment with hydrogen sulfide in the presence of base such as triethylamine.
  • the thiazole is formed from chloroketone 2 as described above.
  • Removal of the t-butoxycarbonyl (Boc) protecting group by treatment with acid such as trifluoroacetic acid in dichloromethane or methanolic hydrogen chloride provides the desired thiazole (la).
  • Thiazoles lb are prepared as illustrated in Scheme 4.
  • Thioamide 8 is treated with the appropriate 2-bromoaldehyde 9 at elevated temperatures, conveniently in an inert solvent such as acetonitrile or acetonitrile/chloroform mixtures at reflux temperature, to provide, after deprotection as described above, thiazole lb.
  • Bromoaldehydes 9 are known in the literature or readily prepared by methods comonly known to those skilled in the art. Conveniently, the corresponding alcohol 10 is oxidized to aldehyde H, for example by treatment with o-iodoxybenzoic acid in DMSO (Frigerio and Santagostino, Tetrahedron Lett. 1994, 35, 8019). Bromination may be accomplished by treatment with a brominating agent, conveniently t- butyldimethylsilyl bromide/DMSO (Bellesia, et. al., J. Chem. Research (S) 1986, 428), to provide the desired bromoaldehydes 9. SCHEME 5.
  • a brominating agent conveniently t- butyldimethylsilyl bromide/DMSO (Bellesia, et. al., J. Chem. Research (S) 1986, 428), to provide the desired bromoaldehydes 9. SCHEME 5.
  • Thiazoles Ic are synthesized as oulined in Scheme 6.
  • the appropriate nitrile 12 which is commercially available, known in the literature, or readily synthesized by methods known to those skilled in the art, is treated with hydrogen sulfide in the presence of a base such as triethylamine, and the resultant thioamide is treated with ⁇ ,4- dibromoacetophenone ( 13) at elevated temperature, conveniently in refluxing ethanol, to provide thiazole 14.
  • This compound is then protected at the 5-position, for example as the 5-trimethylsilyl derivative by treatment with n-butyllithium followed by trimethylsilyl chloride.
  • Thiazoles Id may be prepared as illustrated in Scheme 7.
  • Aminoacetophenone 1_S is prepared from bromo derivative J_3 using a modified Delepine reaction (Goddard, C. J. /. Heterocyclic Chem. 1991, 28, 17), by treatment of compound 13 with hexamethylenetetramine 17 followed by hydrochloric acid in methanol. Amine 18 . is then treated with the appropriate acid chloride to give ketone 20. Formation of the thiazole is accomplished by treatment with Lawesson's reagent at elevated temperature, conveniently in refluxing toluene. The resultant bromo derivative 21 is converted to the desired thiazole Id as described above in Scheme 1 for thiazole la.
  • Acid chlorides 19 are commercially available, known in the literature, or readily prepared using methods commonly known to those skilled in the art.
  • the product I from the reactions described in Schemes 1-7 may be further modified, for example, by the removal of protecting groups or the manipulation of substituents on Rl. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art.
  • Compounds of Formula I contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of Formula I.
  • Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
  • Some of the compounds described herein may exist as tautomers such as keto-enol tautomers.
  • the individual tautomers as well as mixture thereof are encompassed with compounds of Formula I.
  • Compounds of the Formula I may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof.
  • the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent.
  • any enantiomer of a compound of the general Formula I or la may be obtained by stereospecific synthesis using optically pure starting materials of known configuration.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N -dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl- morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such as
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • Compounds of the present invention are potent agonists of the ⁇ 3-adrenoceptor, and as such are useful in treating or preventing diseases, disorders or conditions mediated by the activation of ⁇ 3- adrenoceptor.
  • one aspect of the present invention provides a method for the treatment, control or prevention of such diseases, disorders, or conditions in a mammal which comprises administering to such mammal a therapeutically effective amount of a compound of Formula I.
  • mammal includes human and non-human animals such as dogs and cats and the like.
  • the diseases, disorders or conditions for which compounds of the present invention are useful in treating or preventing include, but are not limited to, (1) diabetes mellitus, (2) hyperglycemia, (3) obesity, (4) hyperlipidemia, (5) hypertriglyceridemia, (6) hypercholesterolemia, (7) atherosclerosis of coronary, cerebrovascular and peripheral arteries, (8) gastrointestinal disorders including peptid ulcer, esophagitis, gastritis and duodenitis, (including that induced by H.
  • any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention.
  • a mammal especially a human with an effective dosage of a compound of the present invention.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
  • compounds of Formula I are administered orally.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the species of mammals being treated, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art of human or veterinary medicine.
  • the compounds of the present invention are administered at a daily dosage of from 0.01 milligram to about 100 milligrams per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form.
  • the total daily dose will generally be from about 0.7 milligrams to about 3500 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • the compounds of the present invention are administered at a daily dosage of from about 0.001 milligram to about 100 milligram per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form.
  • the total daily dose will generally be from about 0.07 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • compositions which comprises a compound of Formula I and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.
  • the compounds of Formula I can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations- being preferred over the liquid preparations.
  • oral liquid preparations such as, for example, suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations- being preferred over the
  • tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
  • the active compounds can also be administered intranasally as, for example, liquid drops or spray.
  • the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • Compounds of formula I may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy- propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • Compounds of Formula I may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds of Formula I are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I.
  • a pharmaceutical composition containing such other drugs in addition to the compound of Formula I is preferred.
  • the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of Formula I.
  • insulin sensitizers including (i) PPAR ⁇ agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, BRL49653 and the like), and compounds disclosed in W097/27857, 97/28115, 97/28137 and 97/27847; (ii) biguanides such as metformin and phenformin; (b) insulin or insulin mimetics;
  • PPAR ⁇ agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, BRL49653 and the like), and compounds disclosed in W097/27857, 97/28115, 97/28137 and 97/27847; (ii) biguanides such as metformin and phenformin; (b) insulin or insulin mimetics;
  • ⁇ -glucosidase inhibitors such as acarbose
  • cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin and pravastatin, fluvastatin, atorvastatin, and other statins), (ii) sequestrants (cholestyramine, colestipol and a dialkylaminoalkyl derivatives of a cross-linked dextran), (ii) nicotinyl alcohol nicotinic acid or a salt thereof, (iii) proliferator- activater receptor agonists such as fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzafibrate), (iv) inhibitors of cholesterol absorption for example beta-sitosterol and (acyl CoA: cholesterol acyltransferase) inhibitors for example melinamide, (v) probucol, (vi) vitamin E, and (vii) thyromimetics;
  • PPAR ⁇ agonists such as those disclosed in W097/28149;
  • antiobesity compounds such as fenfluramine, dexfenfluramine, phentermine, sibutramine, orlistat, and other ⁇ 3 adrenergic receptor agonists;
  • feeding behavior modifying agents such as neuropeptide Y antagonists (e.g. neuropeptide Y5) such as those disclosed in WO 97/19682, WO 97/20820, WO 97/20821 , WO 97/20822 and WO 97/20823;
  • neuropeptide Y antagonists e.g. neuropeptide Y5
  • WO 97/19682 WO 97/20820, WO 97/20821 , WO 97/20822 and WO 97/20823;
  • cAMP production in response to ligand is measured according to Barton et al (1991-, Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. Mol. Pharmacol. v3229:650-658) modified as follows. Chinese hamster ovary (CHO) cells, stably transfected with the cloned ⁇ -adrenergic receptor (Bl , ⁇ 2 or B3) are harvested after 3 days of subculturing.
  • the cell lysate is diluted 5-fold in 0.1 N HCl and then acetylated by the mixture of 150 ⁇ L of acid-diluted sample with 6 ⁇ L of acetylation mixture (acetic anhydride/triethylamine, 1 :2.5).
  • the cAMP produced in response to the ligand is measured in the lysate by competing against l 2 5 ⁇ _ c ]yrp f or binding to a l ⁇ i-cAMP-directed antibody using an automated RIA machine (ATTOFLO, Atto Instruments, Baltimore, MD, Brooker et al 1979, Radioimmunoassay of Cyclic AMP and Cyclic GMP.
  • cAMP level is determined by comparing levels to a standard curve.
  • cAMP is measured using the cAMP SPA kit (code number RPA 556) from Amersham according to the manufacturer's instructions. Samples tested with the latter method do not need to be acetylated.
  • the non-selective, full agonist ⁇ -adrenergic ligand isoproterenol is used at all three receptors to determine maximal stimulation.
  • the human B3 adrenergic receptor (AR) selective ligand (S -N-[4-[2-[[2-hydroxy-3-(4- hy droxyphenoxy )propy 1] amino] ethyl] -phenyl] -4-iodobenzenesulf onamide is used as a control in all assays.
  • Isoproterenol is titrated at a final concentration in the assay of 10" 10 M to 10" 5 M for the B3 AR and 10-11 M t0 ⁇ o-6 M for the Bl AR and B2 AR assays.
  • (S)-N-[4-[2-[[2-Hydroxy-3-(4- hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-4-iodobenzenesulfonamide is titrated at the B3 receptor at concentration of 10 "1 1 M to 10 -6 M.
  • the concentrations used are 10"8 M, 10" 7 M, 3X10" 7 M, 10" 6 M, 3X10"6 M and 10 ⁇ 5 M
  • Unknown ligands are initially tested at the B3 AR at a final concentration in the assay of 10 ⁇ 7 M. Compounds that have an activation at this concentration equal to or greater than 35% of the isoproterenol stimulation are titrated at the B3 AR at concentrations equal to those used to titrate the control (S )-N- [4- [2- [[2-hy droxy-3-(4-hy droxyphenoxy )propyl] amino]ethyl]phenyl]-4-iodobenzenesulfonamide to determine the EC50.
  • the EC50 is defined as the concentration of compound that gives 50% activation of its own maximum.
  • Binding Assay Compounds are also assayed at the Bl and B2 receptors to determine selectivity. This is done for all compounds using a 6 point binding assay as follows: CHO cells expressing the Bl and the B2 receptors are grown for 3-4 days after splitting. The attached cells are washed with PBS and lysed in ImM Tris, pH 7.2 for 10 minutes in ice. The flasks are scraped and the membranes centrifuged at 38,000 x g for 15 minutes at 4 °C.
  • the membranes are resuspended in TME buffer (75 mM Tris, pH 7.4, 12.5 mM MgCl2, 1.5 mM EDTA) at a concentration of 1 mg protein/ml. Large batches of membranes can be prepared, aliquoted and stored at -70°C for up to a year without loss of potency.
  • the binding assay is performed by incubating together membranes (20-50 ⁇ g of protein), the radiolabelled tracer 125 ⁇ _ cyanopindolol ( l 2 5i_CYP, 45pM), and the test compounds at final concentrations ranging from 10-10 M to 10 " 5 M in a final volume of 250 ⁇ L of TME buffer.
  • the tubes are incubated for 1 hour with shaking at room temperature and the samples are filtered in an IMSCO 96-well cell harvester.
  • the filters are counted in a Gamma counter and the data are analyzed using a 4 parameter fit routine in RS 1 (program developed in house using well documented statistical analysis programs) to determine the IC50.
  • the IC50 is defined as the concentration of the compound capable of inhibiting 50% of the binding of the radiolabelled tracer (l 2 5 ⁇ _CYP).
  • a compound's selectivity for the ⁇ 3 receptor may be determined by calculating the ratio (IC50 Bl AR, B2 AR)/(EC50 B3 AR).
  • the yellow oily residue was dissolved in 40 mL of dry ether, cooled in ice, and a solution of hydrochloric acid in methanol (prepared from 0.30 mL of acetyl chloride and 2.0 mL of methanol at 0°C) was added dropwise. After lh, the solution was concentrated under reduced pressure.
  • Step B 2-(4-Bromophenyl)-4-(2-naphthylmethyl)thiazole.
  • Step C 4-[4-(2-Naphthylmethyl)thiazol-2-yl1benzenesulfonyl chloride.
  • a solution of the above aryl bromide (0.53 g) in 10 mL of dry tetrahydrofuran was cooled to -78°C, and a solution of n-butyllithium (1.0 mL of 1.6 M in hexanes) was added dropwise. After 30 min, a steady stream of sulfur dioxide was introduced into the surface of the deep brown-red solution for a period of 5 min. The resulting yellow solution was stirred at -78°C for 10 min, and was then allowed to warm to room temperature.
  • Step A (R -N-[4-r2-[N-(l.l-Dimethylethoxycarbonyl -N-r2-hvdroxy-2- (pyridin-3-yl ethyl]amino1ethyl]phenyl]-4-aminothiocarbonyl benzene sulfonamide.
  • Step B (R -N-r4-r2-r[2-Hvdroxy-2-(pyridin-3-yl ethvnaminolethyll phenyl1-4-r4-(4-trifluoromethylphenyl)thiazol-2-yl1benzenesulfonamide.
  • Step A ⁇ -Amino-4-bromoacetophenone hydrochloride.
  • the general procedure for the modified Delepine reaction (Goddard, C. J. J. Heterocyclic Chem. 1991, 28, 17) was used.
  • the precipitated solid was collected, washed with chloroform, dried in vacuo, and was then suspended in a mixture of 6 mL of concentrated hydrochloric acid and 30 mL of methanol and stirred overnight.
  • the precipitated solid was collected, washed with methanol and dried in vacuo, affording 1.38 g of white powder, which was used without further purification.
  • Step B ⁇ -Amino-4-bromoacetophenone 4-(Trifluoromethyl benzamide.
  • a mixture of the above hydrochloride salt (1.38 g) and triethylamine (1.50 mL) in 40 mL of chloroform was cooled in an ice- water bath, and a solution of 4- (trifluoromethyl)benzoyl chloride (1.21 g) in 5 mL of chloroform was added dropwise. The mixture was stirred at 0°C for 1 h, diluted with 30 mL of chloroform and washed sequentially with water, 5% aqueous hydrochloric acid, saturated aqueous sodium bicarbonate and saturated brine.
  • Step C 5-(4-Bromophenyl -2-(4-Trifluoromethylphenyl)thiazole.
  • Step D 5-(4-Chlorosulfonylphenyl)-2-(4-Trifluoromethylphenyl thiazole.
  • a solution of the above aryl bromide (0.356 g) in 6 mL of dry THF was treated with n-butyllithium (0.63 mL of 1.6 M in hexanes), followed by sulfur dioxide and then N-chlorosuccinimide as described in Example 1 , Step C above.
  • Step E (R -N-r4-r2-r[2-Hvdroxy-2-(p ⁇ ridin-3-yl ethyllaminolethyll phenyll-4-[2-(4-trifluoromethylphenyl)thiazol-5-yl1benzenesulfonamide
  • a solution of 0.131 g of (R)-N-[2-[4-(aminophenyl)]ethyl]-2-hydroxy-2- (pyrid-3-yl)ethylcarbamic acid 1,1-dimethylethyl ester in 1.6 mL of dichloromethane was treated with the above sulfonyl chloride (0.171 g) and 0.040 mL of pyridine, followed by addition of trifluoroacetic acid, as described in Example 1, Step D.
  • Step B (R -N-[4-r2-r[2-Hvdroxy-2-(pyridin-3-yDethyllaminolethyll phenyll-4-[5-(4-fluorophenyl)thiazol-2-ynbenzenesulfonamide.
  • Step A 4-(Trifluoromethyl )thiobenzamide.
  • 4-(Trifluoromethyl)benzonitrile (3.42 g) was treated with triethylamine (2.12 g) and hydrogen sulfide in pyridine solution as described in Example 2, Step A.
  • Step B 4-(4-Bromophenyl)-2-(4-Trifluoromethylphenyl thiazole.
  • Step C 4-f4-Bromophenyl)-2-(4-Trifluoromethylphenyl)-5- ftrimethylsilyPthiazole.
  • a solution of the aryl bromide obtained above (0.576 g) in 10 mL of dry tetrahydrofuran (THF) was cooled in a dry ice-acetone bath, and a solution of n-butyllithium (1.0 mL of 1.6 M in hexanes) was added dropwise. After an additional 10 min, trimethylsilyl chloride (0.196 g, 0.23 mL) was added in one portion. After an additional 15 min, the cooling bath was removed, and the reaction mixture was allowed to warm to room temperature over 1 h.
  • Step D 4-f4-Chlorosulfonylphenyl -2-(4-Trifluoromethylphenyl)-5- (trimethy lsily Dthiazole .
  • the aryl bromide from above (0.456 g) was treated with n-butyllithium, followed by sulfur dioxide and then N-chlorosuccinimide as described in Example 1, Step C above.
  • the crude product (0.223 g) was used without further purification.
  • Step E (RVN-r4-r2-rr2-Hvdroxy-2-(pyridin-3-yl ethyllaminolethyllphenyn-4- [2-( , 4-trifluoromethylphenyl)thiazol-4-yllbenzenesulfonamide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Thiazole substituted benzenesulfonamides are β3 adrenergic receptor agonists with very litte β1 and β2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduce neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

Description

TITLE OF THE INVENTION
THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR
THE TREATMENT OF DIABETES AND OBESITY
BACKGROUND OF THE INVENTION β-Adrenoceptors have been subclassified as βl and β2 since 1967. Increased heart rate is the primary consequence of βl -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from β2 stimulation. Adipocyte lipolysis was initially thought to be solely a βl -mediated process. However, more recent results indicate that the receptor mediating lipolysis is atypical in nature. These atypical receptors, later called β3-adrenoceptors, are found on the cell surface of both white and brown adipocytes where their stimulation promotes both lipolysis (breakdown of fat) and energy expenditure. Early developments in this area produced compounds with greater agonist activity for the stimulation of lipolysis (β3 activity) than for stimulation of atrial rate (βl) and tracheal relaxation (β2). These early developments disclosed in Ainsworth et al., U.S. Patents 4,478,849 and 4,396,627, were derivatives of phenylethanolamines. Such selectivity for β3-adrenoceptors could make compounds of this type potentially useful as antiobesity agents. In addition, these compounds have been reported to show antihyperglycemic effects in animal models of non-insulin-dependent diabetes mellitus.
A major drawback in treatment of chronic diseases with β3 agonists is the potential for stimulation of other β-receptors and subsequent side effects. The most likely of these include muscle tremor (β2) and increased heart rate (βl). Although these phenylethanolamine derivatives do possess some β3 selectivity, side effects of this type have been observed in human volunteers. It is reasonable to expect that these side effects resulted from partial βl and/or β2 agonism.
More recent developments in this area are disclosed in Ainsworth et aL, U.S. Patent 5,153,210, Caulkett et al., U.S. Patent 4,999,377, Alig et al., U.S. Patent 5,017,619, Lecount et al., European Patent 427480 and Bloom et al., European Patent 455006. Even though these more recent developments purport to describe compounds with greater β3 selectivity over the βl and β2 activities, this selectivity was determined using rodents, in particular, rats as the test animal. Because even the most highly selective compounds, as determined by these assays, still show signs of side effects due to residual βl and β2 agonist activity when the compounds are tested in humans, it has become apparent that the rodent is not a good model for predicting human β3 selectivity.
Recently, assays have been developed which more accurately predict the effects that can be expected in humans. These assays utilize cloned human β3 receptors which have been expressed in Chinese hamster ovary cells. See Emorine et al, Science, 1989, 245: 1118- 1121; Liggett, Mol. Pharmacol.. 1992, 42:634-637; and Grannemann et al., Mol. Pharmacol.. 1992, 42: 964-970. The agonist and antagonist effects of the various compounds on the cultivated cells provide an indication of the antiobesity and antidiabetic effects of the compounds in humans.
US Patent 5,451,677 discloses selective B3 agonists of the formula:
Figure imgf000004_0001
US Patent 5,561,142 published November 2, 1995 discloses selective B3 agonists of the formula
Figure imgf000004_0002
Compounds of the present invention that are within the generic disclosure of US Patent 5,561,142 represent a novel selection thereof.
SUMMARY OF THE INVENTION
The instant invention is concerned with thiazole substituted benzenesulfonamides which are useful as antiobesity and antidiabetic compounds. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the substituted sulfonamides. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof. Further objects will become apparent from reading the following description.
DESCRIPTION OF THE INVENTION
The present invention provides compounds having the formula I:
Figure imgf000005_0001
wherein
X is (1) a bond,
(2) C1-C3 alkylene, optionally substituted with 1 or 2 groups selected from methyl and halogen,
(3) C1-C3 alkylene wherein said alkylene contains an oxygen, optionally substituted with 1 or 2 groups selected from methyl and halogen; m is 0 to 5; A is (1) phenyl, (2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(3) a benzene ring fused to a C5-C10 carbocyclic ring,
(4) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or
(5) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5-C10 carbocyclic ring;
Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy,
(b) halogen, (c) cyano,
(d) QR2,
(e) C3-C8 cycloalkyi,
(f) A optionally substituted with up to 5 groups selected from halogen, Cl-ClO alkyl and Cl-ClO alkoxy, (g) Q'COR3,
(h) S(0)nR3, where n is 0 to 2,
(i) NR2S02R3,
(j) NR2C02R2, and
(k) CO2R2, (2) C3-C8 cycloalkyi,
(3) oxo,
(4) halogen,
(5) cyano,
(6) QR2, (7) S(0)nR3, where n is 0 to 2,
(8) Q'COR3,
(9) NR2Sθ2R3,
(10) NR2C02R2, (11) A optionally substituted with up to 5 groups independently selected from
(a) R2,
(b) QR2, (c) halogen, and
(d) oxo; or
(12) CO2R2; R2 is (1) hydrogen,
(2) Cl-ClO alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy,
(b) halogen,
(c) C02R4,
(d) S(O)n-Cl-Cl0 alkyl, where n is 0 to 2, (e) C3-C8 cycloalkyi,
(f) Cl-ClO alkoxy, and
(g) A optionally substituted with up to 5 groups selected from halogen, Cl-ClO alkyl and Cl-ClO alkoxy,
(3) C3-C8 cycloalkyi, or (4) A optionally substituted with up to 5 groups selected from
(a) halogen,
(b) nitro,
(c) oxo, (d) NR4R4,
(e) Cl-ClO alkoxy,
(f) S(O)n-Cl-Cl0 alkyl where n is 0 to 2, and
(g) Cl-ClO alkyl optionally substituted with up to 5 groups selected from hydroxy, halogen, CO2R , S(O)n-Cl-CK) alkyl, where n is 0 to 2, C3-C8 cycloalkyi, Cl-ClO alkoxy, and A optionally substituted with up to 5 groups selected from halogen, Cl-ClO alkyl and Cl-ClO alkoxy; R3 is (1) R2 or (2) NR2R2;
R4 is (1) H, or
(2) Cl-Cio alkyl;
Q is (1) N(R2),
(2) O or
(3) S(0)n, and n is 0 to 2;
Q' is (1) N(R2),
(2) O or
(3) a bond; or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
One subset of compounds of formula I provides compounds wherein
X is (1) a bond,
(2) CH2 (3) CH2O, wherein C is attached to thiazole, and O is attached to A;
Another subset of compounds of formula I provides compounds wherein
Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 halogens;
(2) halogen,
(3) QR2,
(4) Q'COR3,
(5) phenyl; R2 is (1) hydrogen,
(2) Cl-ClO alkyl optionally substituted with up to 5 halogens; R is (1) Cl-Cio alkyl; and
Q is (1) O. There is one subset of compounds of formula I wherein the thiazolyl moiety is attached to the benzenesulfonamide moiety via the carbon at the 2 position (C2) of the thiazole ring. There is another subset of compounds of formula I wherein the thiazolyl moiety is attached to X, or where X is a bond, directly to A via the carbon at the 2 position of the thiazole ring. Preferably, either the benzenesulfonamide moiety or X (or A, if X is a bond) is attached to the C2 of the thiazole ring, and the other to the C4 positions of the thiazole ring.
Another subset of compounds of formula I provides compounds wherein A is selected from phenyl, naphthyl, a 5 or 6- membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygenk sulfur and nitrogen fused to a benzene ring, and a 5 or 6- membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen. Preferably, A is selected from phenyl, naphthyl, thienyl, pyridinyl, benzothienyl, quinolinyl, indolyl, and benzofuranyl.
In a preferred embodiment of compounds of formula I X is (1) a bond,
(2) CH2, (3) CH2O, wherein C is attached to thiazole, and O is attached to A; m is 0 to 5;
A is (1) phenyl,
(2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(3) a benzene ring fused to a C5-C10 carbocyclic ring,
(4) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or
(5) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5-C10 carbocyclic ring;
Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 halogens;
(2) halogen,
(3) QR2,
(4) Q'COR3,
(5) phenyl; R2 is (1) hydrogen,
(2) Cl-ClO alkyl optionally substituted with up to 5 halogens;
R3 is (1) Cl-ClO alkyl; and Q is (1) 0; or a pharmaceutically acceptable salt thereof.
In a more preferred embodiment are compounds of formula I wherein
X is (1) a bond, (2) CH2,
(3) CH2O, wherein C is attached to thiazole, and O is attached to A; m is 0 to 5;
A is (1) phenyl, (2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(3) naphthyl, or
(4) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a benzene ring;
Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 halogens; (2) halogen,
(3) QR2, ( (44)) Q'COR3,
(5) phenyl;
R is (1) hydrogen,
(2) Cl-ClO alkyl optionally substituted with up to 5
Figure imgf000010_0001
ClO alkyl; and
Q is (1) O; and either the benzenesulfonamide moiety or X (or A, if X is a bond) is attached to the C2 of the thiazole ring, and the other to the C4 positions of the thiazole ring; or a pharmaceutically acceptable salt thereof.
Compounds of the present invention that are within the generic structure disclosed in US Patent 5,561,142 represent a novel selection thereof. The present compounds are potent B3 agonists, and have improved oral bioavailability in animals.
Representative antiobesity and antidiabetic compounds of the present invention include the following: l. N-[4-[2-[[.2-hydroxy-2-(3-ρyridinyl)ethyl]aminolethyl]ρhenyll-4-[4-(2- naphthylmethyl)thiazol-2-yl]benzenesulfonamide; 2. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
3. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [4- (trifluoromethoxy )pheny 1 j thiazol-2-y 1] benzenesulfonamide ;
4. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3,4-difluorophenylmethyl)thiazol-2-yl]benzenesulfonamide;
5. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyll-4-[4- (3-pyridyl)thiazol-2-yl]benzenesulfonamide;
6. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyllamino]ethyllphenyl]-4-[4- (4-fluorophenylmethyl)thiazol-2-yl]benzenesulfonamide; 7. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyll-4-[4- (3,4-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
8. N- [4- [2- [ [2-hydroxy-2- (pyridin-3 -yl)ethyl] amino] ethyl] phenyl] -4- [4- [4-(trifluoromethyl)phenylmethyl]thiazol-2-yl]benzenesulfonamide;
9. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (2-pyridyl)thiazol-2-yl]benzenesulfonamide;
10. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [l-(2-phenyl)ethyl]thiazol-2-yl]benzenesulfonamide;
11. N- [4- [2- [ [2-hydroxy-2-(pyridin-3-yl)ethyl] amino]ethyl]phenyl] -4- [4- (4-fluorophenyl)thiazol-2-yl]benzenesulfonamide; 12. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (2-naphthyl)thiazol-2-yl]benzenesulfonamide;
13. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3,4,5-trifluorophenyl)thiazol-2-yl]benzenesulfonamide; 14. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (4-hexylphenyl)thiazol-2-yl]benzenesulfonamide;
15. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [4-(trifluoromethoxy)phenylmethyl]thiazol-2-yl]benzenesulfonamide; 16. N- [4- [2- [ [2-hy droxy-2-(pyridin-3-yl)ethyl] amino] ethyl]phenyl] -4- [4- [4-(trifluoromethoxy)phenoxymethyl]thiazol-2-yl]benzenesulfonamide;
17. N- [4- [2- [ [2-hydroxy-2-(pyridin-3-yl)ethyl] amino] ethyl]phenyl] -4- [4- (2-benzo[b]thienyl)thiazol-2-yl]benzenesulfonamide;
18. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3-quinolinyl)thiazol-2-yl]benzenesulfonamide;
19. N- [4- [2- [ [2-hydroxy-2-(pyridin-3-yl)ethyl] amino]ethyl]phenyl] -4- [4- (6-quinolinyl)thiazol-2-yl]benzenesulfonamide;
20. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (2-benzo[/?]furyl)thiazol-2-yl]benzenesulfonamide; 21. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-
(3-indolyl)thiazol-2-yl]benzenesulfonamide;
22. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-
(2,4-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
23. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3,5-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
24. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [4-(l,l-dimethylethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
25. N- [4- [2- [ [2-hy droxy-2- (pyridin- 3-y l)ethy 1] amino] ethyl]phenyl] -4- [4- (2,3-difluorophenyl)thiazol-2-yl]benzenesulfonamide; 26. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [3-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; 27. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [4-(difluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; 28. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (2,4-dichlorophenyl)thiazol-2-yl]benzenesulfonamide;
29. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-
[2-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
30. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-
[2-fluoro-4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; 31. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [4-fluoro-2-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
32. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [2,4-bis(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; 33. N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[5- (4-fluorophenyl)thiazol-2-yl]benzenesulfonamide;
34. N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[2- (4-trifluoromethylphenyl)thiazol-4-yl]benzenesulfonamide;
35. N- [4- [2- [ [2-Hy droxy-2- (pyridin- 3-y l)ethyl] amino] ethy l]pheny 1] -4- [2- (4-trifluoromethylphenyl)thiazol-5-yl]benzenesulfonamide;
36. N- [4- [2- [ [2-hy droxy-2-(pyridin-3 -y l)ethy 1] amino] ethyl]pheny 1] -4- [4- (4-phenylphenyl)thiazol-2-yl]benzenesulfonamide; 37. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3,4-dihydroxyphenyl)thiazol-2-yl]benzenesulfonamide; 38. N- [4- [2- [ [2-hy droxy-2-(pyridin-3-yl)ethyl] amino]ethyl]phenyl] -4- [4- (4-hydroxyphenyl)thiazol-2-yl]benzenesulfonamide;
39. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (4-acetoxyphenyl)thiazol-2-yl]benzenesulfonamide;
40. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (4-acetamidophenyl)thiazol-2-yl]benzenesulfonamide;
41. N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[2- (4-trifluoromethoxyphenyl)thiazol-4-yl]benzenesulfonamide.
The compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in structural Formula I. Additional asymmetric centers may be present on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof, be included within the ambit of the instant invention. In the case of the asymmetric center represented by the asterisk in Formula I, it has been found that the compound in which the hydroxy substituent is above the plane of the structure, as seen in Formula Ic, is more active and thus more preferred over the compound in which the hydroxy substituent is below the plane of the structure. The following stereospecific structure represents the preferred stereoisomers of the instant invention:
Figure imgf000014_0001
The thiazolyl moiety is numbered as follows:
Figure imgf000014_0002
1 Throughout the instant application, the following terms have the indicated meanings: "Alkylene" means -(CH2)ρ- where p is the designated carbon number; one or two of the hydrogen may be optionally replaced by methyl or halogen. Where the optionally substituted alkylene contains an oxygen, the oxygen may be at either end of the alkylene chain, or it may be embedded within the chain. Examples include OCH2, CH20, CH2OCH2, C(CH3)2θ, etc.
The alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration. Exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
The alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like. The term "halogen" is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.
The term "carbocyclic ring" is intended to include both aromatic and nonaromatic rings containing only carbon atoms. Thus, a benzene ring fused to a C5-C10 carbocyclic ring, includes naphthyl, tetrahydronaphthyl, indanyl and indenyl. A 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5-C10 carbocyclic ring includes benzene fused to a heterocyclic ring as well as a non-aromatic carbocyclic ring fused to a heterocyclic ring. The carbocyclic ring preferably is C5-C7. A 5 and 6-membered heterocyclic ring, whether isolated or as a part of a fused ring system, is intended to include aromatic and unsaturated non-aromatic heterocycles; and where the heterocycle is part of a fused ring, at least one of the rings is aromatic. Examples of a 5 or 6- membered ring include pyridyl, pyrimidinyl, pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, oxazolyl, imidazolidinyl, pyrazolyl, isoxazolyl. Examples of a benzene ring fused to a 5 or 6-membered heterocyclic ring include benzothiadiazolyl, indolyl, indolinyl, benzodioxolyl, benzodioxanyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazinyl, benzisoxazolyl, benzothiazolyl, 2,3-dihydrobenzofuranyl, quinolinyl, benzotriazolyl, benzoxazolyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4- tetrahydroquinolinyl. Examples of a 5 or 6-membered heterocyclic ring fused to a 5 or 6-membered heterocyclic ring incude purmyl, furopyridine and thienopyridme. Examples of a 5 or 6-membered heterocyclic ring fused to a non-aromatic carbocyclic ring include tetrahydrobenzothiazolyl, 5,6,7,8-tetrahydroquinolinyl, 2,3- cyclopentenopyridyl, 4,5,6,7-tetrahydroindolyl, 5,6,7,8- tetrahydroisoquinolyl, 5,6,7, 8-tetrahydroquinoxalinyl. The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
Throughout the instant application, when reference is made to "compounds of Formula I" it is meant to include, unless otherwise specified, pharmaceutically acceptable salts and prodrugs thereof. Prodrugs are derivatives of compounds of Formula I that are transformed in vivo to the active drug molecule; prodrugs include derivatives of free hydroxy, amino or carboxylic groups such as esters, ethers, amides, carbonates, carbamates, and N-alkyl derivatives. Specific examples of prodrugs of compounds of Formula I include: (a) derivation of the secondary amine such as N-alkylation (methyl, ethyl, isopropyl and 2- methoxy ethyl), and N-acylation (1-pyrrolidinylacetyl, 4- morpholinylacetyl, (l-acetoxy)ethoxycarbonyl, and dimethylaminoacetyl); (b) derivation of the secondary hydroxy such as O-alkylation (ethyl) and O-acylation (acetyl, t-butoxycarbonyl, benzoyl, cyclopropylcarbonyl); and (c) the vicinally positioned secondary amine and secondary hydroxy taken together form a group of the formula
Figure imgf000016_0001
wherein. U and V are independently a bond, carbonyl, methylene, CH(OH) or C(OH)(CH3). Prodrugs of the above-described types may be readily prepared from compounds of Formula I using methods well know to persons skilled in the art.
Certain of the above defined terms may occur more than once in the above formula and upon such occurrence each term shall be defined independently of the other; thus for example, NR2R2 may represent NH2, NHCH3, N(CH3)CH2CH3, and the like. The compounds (I) of the present invention can be prepared as described in the following schemes. Thiazoles la, lb and Ic are prepared via the Hantzsch thiazole synthesis (Sainsbury, M. In "Rodd's Chemistry of Carbon Compounds", Coffey, S., Ausell, M. F., Eds.; Elsevier: Amsterdam, 1986; Vol. IV C, 399-455) from the appropriate thioamide and 2-halocarbonyl derivative. As illustrated in Scheme 1 for thiazoles la, 4-bromothiobenzamide (E.P. Papadopopoulos, /. Org. Chem. 1976, 41, 962) is condensed with the appropriate chloroketone 2, typically by heating in ethanol at reflux for 6 to 24 hours, to give bromophenylthiazole 3.. Treatment with n-butyllithium, conveniently in tetrahydrofuran at -78 °C, followed by sulfur dioxide, with warming to ambient temperature, provides the resultant lithium sulfinate. This may be readily converted to the corresponding sulfonyl chloride 4 by treatment with a chlorinating agent such as N-chlorosuccimide. The protected aniline derivative 5 (Fisher, et. al, US 5,561,142, Oct. 1, 1996) is treated with sulfonyl chloride 4, and a base such as pyridine in an anhydrous solvent such as dichloromethane or chloroform for 0.5 to 24 hours at temperatures of -20 to 50°C, preferably 0°C, followed by removal of the protecting group with, in the case of a tert-butylcarbamate, acid such as trifluoroacetic acid or methanolic hydrogen chloride, provides the thiazole la.
SCHEME 1.
Figure imgf000018_0001
Figure imgf000018_0002
The chloroketones 2 are commercially available, known in the literature, or readily prepared by methods commonly known to those skilled in the art. Conveniently, the corresponding acid chloride 6 is treated with diazomethane followed by hydrogen chloride to provide chloroketone 2, as illustrated in Scheme 2.
SCHEME 2.
Figure imgf000019_0001
An alternate approach for the synthesis of thiazoles la is illustrated in Scheme 3. Nitrile 7 (Fisher, et. al, US 5,561,142, Oct. 1, 1996) is converted to the corresponding thiamide by treatment with hydrogen sulfide in the presence of base such as triethylamine. The thiazole is formed from chloroketone 2 as described above. Removal of the t-butoxycarbonyl (Boc) protecting group by treatment with acid such as trifluoroacetic acid in dichloromethane or methanolic hydrogen chloride provides the desired thiazole (la).
SCHEME 3.
Figure imgf000020_0002
Et3N, pyridine
Figure imgf000020_0001
Figure imgf000020_0003
2
2) TFA/CH2CI2
Figure imgf000020_0004
Thiazoles lb are prepared as illustrated in Scheme 4. Thioamide 8 is treated with the appropriate 2-bromoaldehyde 9 at elevated temperatures, conveniently in an inert solvent such as acetonitrile or acetonitrile/chloroform mixtures at reflux temperature, to provide, after deprotection as described above, thiazole lb.
SCHEME 4.
Figure imgf000021_0001
9
2) TFA/CH2CI2
Figure imgf000021_0002
Bromoaldehydes 9 are known in the literature or readily prepared by methods comonly known to those skilled in the art. Conveniently, the corresponding alcohol 10 is oxidized to aldehyde H, for example by treatment with o-iodoxybenzoic acid in DMSO (Frigerio and Santagostino, Tetrahedron Lett. 1994, 35, 8019). Bromination may be accomplished by treatment with a brominating agent, conveniently t- butyldimethylsilyl bromide/DMSO (Bellesia, et. al., J. Chem. Research (S) 1986, 428), to provide the desired bromoaldehydes 9. SCHEME 5.
Figure imgf000022_0001
Figure imgf000022_0002
Thiazoles Ic are synthesized as oulined in Scheme 6. The appropriate nitrile 12, which is commercially available, known in the literature, or readily synthesized by methods known to those skilled in the art, is treated with hydrogen sulfide in the presence of a base such as triethylamine, and the resultant thioamide is treated with α,4- dibromoacetophenone ( 13) at elevated temperature, conveniently in refluxing ethanol, to provide thiazole 14. This compound is then protected at the 5-position, for example as the 5-trimethylsilyl derivative by treatment with n-butyllithium followed by trimethylsilyl chloride. Conversion of the resultant bromo derivative 15 to the corresponding sulfonyl chloride followed by sulfonamide formation with aniline 5 and removal of the Boc protecting group with TFA occurs as described above for Scheme 1. The silyl group is then removed, conveniently by treatment with hydrogen fluoride in acetonitrile, to provide the desired thiazole Ic.
SCHEME 6.
Figure imgf000023_0001
Thiazoles Id may be prepared as illustrated in Scheme 7. Aminoacetophenone 1_S is prepared from bromo derivative J_3 using a modified Delepine reaction (Goddard, C. J. /. Heterocyclic Chem. 1991, 28, 17), by treatment of compound 13 with hexamethylenetetramine 17 followed by hydrochloric acid in methanol. Amine 18. is then treated with the appropriate acid chloride to give ketone 20. Formation of the thiazole is accomplished by treatment with Lawesson's reagent at elevated temperature, conveniently in refluxing toluene. The resultant bromo derivative 21 is converted to the desired thiazole Id as described above in Scheme 1 for thiazole la.
Acid chlorides 19 are commercially available, known in the literature, or readily prepared using methods commonly known to those skilled in the art.
SCHEME 7.
Figure imgf000025_0001
21
Figure imgf000025_0002
In some cases, the product I from the reactions described in Schemes 1-7 may be further modified, for example, by the removal of protecting groups or the manipulation of substituents on Rl. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art. .Compounds of Formula I contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of Formula I. Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
Some of the compounds described herein may exist as tautomers such as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of Formula I. Compounds of the Formula I may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent.
Alternatively, any enantiomer of a compound of the general Formula I or la may be obtained by stereospecific synthesis using optically pure starting materials of known configuration. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N -dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl- morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
Compounds of the present invention are potent agonists of the β3-adrenoceptor, and as such are useful in treating or preventing diseases, disorders or conditions mediated by the activation of β3- adrenoceptor. Thus one aspect of the present invention provides a method for the treatment, control or prevention of such diseases, disorders, or conditions in a mammal which comprises administering to such mammal a therapeutically effective amount of a compound of Formula I. The term "mammal" includes human and non-human animals such as dogs and cats and the like. The diseases, disorders or conditions for which compounds of the present invention are useful in treating or preventing include, but are not limited to, (1) diabetes mellitus, (2) hyperglycemia, (3) obesity, (4) hyperlipidemia, (5) hypertriglyceridemia, (6) hypercholesterolemia, (7) atherosclerosis of coronary, cerebrovascular and peripheral arteries, (8) gastrointestinal disorders including peptid ulcer, esophagitis, gastritis and duodenitis, (including that induced by H. pylori), intestinal ulcerations (including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis) and gastrointestinal ulcerations, (9) neurogenic inflammation of airways, including cough, asthma, (10) depression, (11) prostate diseases such as benign prostate hyperplasia, (12) irritable bowel syndrome and other disorders needing decreased gut motility, and (13) elevated intraocular pressure and glaucoma. Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Preferably compounds of Formula I are administered orally.
The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the species of mammals being treated, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art of human or veterinary medicine.
When treating obesity (in conjunction with diabetes and/or hyperglycerriia, or alone) in human or non-human animals such as dogs and cats, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from 0.01 milligram to about 100 milligrams per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.7 milligrams to about 3500 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
When treating diabetes mellitus and/or hyperglycemia, as well as other diseases or disorders for which compounds of formula I are useful, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.001 milligram to about 100 milligram per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.07 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
Another aspect of the present invention provides pharmaceutical compositions which comprises a compound of Formula I and a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.
The compositions include compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well- known in the art of pharmacy.
In practical use, the compounds of Formula I can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations- being preferred over the liquid preparations.
Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally as, for example, liquid drops or spray.
The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
Compounds of formula I may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy- propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
Compounds of Formula I may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds of Formula I are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I. When a compound of Formula I is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of Formula I is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of Formula I. Examples of other active ingredients that may be combined with a compound of Formula I, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (a) insulin sensitizers including (i) PPARγ agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, BRL49653 and the like), and compounds disclosed in W097/27857, 97/28115, 97/28137 and 97/27847; (ii) biguanides such as metformin and phenformin; (b) insulin or insulin mimetics;
(c) sulfonylureas such as tolbutamide and glipizide;
(d) α-glucosidase inhibitors (such as acarbose),
(e) cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin and pravastatin, fluvastatin, atorvastatin, and other statins), (ii) sequestrants (cholestyramine, colestipol and a dialkylaminoalkyl derivatives of a cross-linked dextran), (ii) nicotinyl alcohol nicotinic acid or a salt thereof, (iii) proliferator- activater receptor agonists such as fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzafibrate), (iv) inhibitors of cholesterol absorption for example beta-sitosterol and (acyl CoA: cholesterol acyltransferase) inhibitors for example melinamide, (v) probucol, (vi) vitamin E, and (vii) thyromimetics;
(f) PPARδ agonists such as those disclosed in W097/28149; (g) antiobesity compounds such as fenfluramine, dexfenfluramine, phentermine, sibutramine, orlistat, and other β3 adrenergic receptor agonists;
(h) feeding behavior modifying agents such as neuropeptide Y antagonists (e.g. neuropeptide Y5) such as those disclosed in WO 97/19682, WO 97/20820, WO 97/20821 , WO 97/20822 and WO 97/20823;
(i) PPARα agonists such as described in WO 97/36579 by Glaxo;
(j) PPARγ antagonists as described in WO97/10813; and (k) serotonin reuptake inhibitors such as fluoxetine and sertraline
The following in vitro assays are suitable for screening compounds for B3 agonist activity and for determining selectivity for the B3 receptor over the Bl/ B2 receptors: Functional Assay: cAMP production in response to ligand is measured according to Barton et al (1991-, Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. Mol. Pharmacol. v3229:650-658) modified as follows. Chinese hamster ovary (CHO) cells, stably transfected with the cloned β-adrenergic receptor (Bl , β2 or B3) are harvested after 3 days of subculturing. Harvesting is done with Enzyme-free Dissociation Media (Specialty Media). Cells are counted and distributed in the assay tubes, after being resuspended in Tris buffer (ACC buffer: 75 mM Tris, pH 7.4, 250 mM Sucrose, 12.5 mM MgCl2, 1.5 mM EDTA, 0.2 mM Sodium Metabisulfite, 0.6mM IBMX) containing an antioxidant and a phosphodiesterase inhibitor. Reaction is initiated by mixing 200,000 cells in 100 μL with 20 μL of a 6x stock of ligand/unknown to be tested. Tubes shake at 275 rpm for 45 min at room temperature. The reaction is stopped by boiling the tubes for 3 min. The cell lysate is diluted 5-fold in 0.1 N HCl and then acetylated by the mixture of 150 μL of acid-diluted sample with 6 μL of acetylation mixture (acetic anhydride/triethylamine, 1 :2.5). The cAMP produced in response to the ligand is measured in the lysate by competing against l25χ_c ]yrp for binding to a l^i-cAMP-directed antibody using an automated RIA machine (ATTOFLO, Atto Instruments, Baltimore, MD, Brooker et al 1979, Radioimmunoassay of Cyclic AMP and Cyclic GMP.
Advances in Cyclic Nucleotide Research, vol 10: 1-32.). The unknown cAMP level is determined by comparing levels to a standard curve. Alternatively, cAMP is measured using the cAMP SPA kit (code number RPA 556) from Amersham according to the manufacturer's instructions. Samples tested with the latter method do not need to be acetylated.
The non-selective, full agonist β-adrenergic ligand isoproterenol is used at all three receptors to determine maximal stimulation. The human B3 adrenergic receptor (AR) selective ligand (S -N-[4-[2-[[2-hydroxy-3-(4- hy droxyphenoxy )propy 1] amino] ethyl] -phenyl] -4-iodobenzenesulf onamide is used as a control in all assays. Isoproterenol is titrated at a final concentration in the assay of 10"10 M to 10"5 M for the B3 AR and 10-11 M t0 ιo-6 M for the Bl AR and B2 AR assays. (S)-N-[4-[2-[[2-Hydroxy-3-(4- hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-4-iodobenzenesulfonamide is titrated at the B3 receptor at concentration of 10"11 M to 10-6 M. At the Bl AR the concentrations used are 10"8 M, 10"7 M, 3X10"7 M, 10"6 M, 3X10"6 M and 10~5 M For the B2 AR a single concentration of 10"5 M is used.
Unknown ligands are initially tested at the B3 AR at a final concentration in the assay of 10~7 M. Compounds that have an activation at this concentration equal to or greater than 35% of the isoproterenol stimulation are titrated at the B3 AR at concentrations equal to those used to titrate the control (S )-N- [4- [2- [[2-hy droxy-3-(4-hy droxyphenoxy )propyl] amino]ethyl]phenyl]-4-iodobenzenesulfonamide to determine the EC50. The EC50 is defined as the concentration of compound that gives 50% activation of its own maximum. Data are analyzed using the Prism program (GraphPan, San Diego, CA). Binding Assay: Compounds are also assayed at the Bl and B2 receptors to determine selectivity. This is done for all compounds using a 6 point binding assay as follows: CHO cells expressing the Bl and the B2 receptors are grown for 3-4 days after splitting. The attached cells are washed with PBS and lysed in ImM Tris, pH 7.2 for 10 minutes in ice. The flasks are scraped and the membranes centrifuged at 38,000 x g for 15 minutes at 4 °C. The membranes are resuspended in TME buffer (75 mM Tris, pH 7.4, 12.5 mM MgCl2, 1.5 mM EDTA) at a concentration of 1 mg protein/ml. Large batches of membranes can be prepared, aliquoted and stored at -70°C for up to a year without loss of potency. The binding assay is performed by incubating together membranes (20-50 μg of protein), the radiolabelled tracer 125 τ_ cyanopindolol (l 25i_CYP, 45pM), and the test compounds at final concentrations ranging from 10-10 M to 10"5 M in a final volume of 250 μL of TME buffer. The tubes are incubated for 1 hour with shaking at room temperature and the samples are filtered in an IMSCO 96-well cell harvester. The filters are counted in a Gamma counter and the data are analyzed using a 4 parameter fit routine in RS 1 (program developed in house using well documented statistical analysis programs) to determine the IC50. The IC50 is defined as the concentration of the compound capable of inhibiting 50% of the binding of the radiolabelled tracer (l25ι_CYP). A compound's selectivity for the β3 receptor may be determined by calculating the ratio (IC50 Bl AR, B2 AR)/(EC50 B3 AR).
The following examples are provided so that the invention might be more fully understood. They should not be construed as limiting the invention in any way.
EXAMPLE 1
Figure imgf000035_0001
(RVN-r4-r2-[[2-Hydroxy-2-(pyridin-3-yl ethyllaminolethyllphenyll-4-r4- (2-naphthylmethyl thiazol-2-yl]benzenesulfonamide Step A. 2-Naphthylmethyl chloromethyl ketone. A mixture of
2-naphthylacetic acid (0.75 g) and 5 mL of thionyl chloride was warmed at reflux for 1 h. Excess thionyl chloride was removed under reduced pressure, followed by azeotropic distillation with two portions of benzene. The residual yellow liquid was dissolved in 10 mL of dry ether and was added dropwise to an ice-cold solution of excess diazomethane etherate (generated from Diazald and aqueous potassium hydroxide at 0°C). The reaction mixture was stirred at 0°C for 1 h, and was then concentrated under reduced pressure. The yellow oily residue was dissolved in 40 mL of dry ether, cooled in ice, and a solution of hydrochloric acid in methanol (prepared from 0.30 mL of acetyl chloride and 2.0 mL of methanol at 0°C) was added dropwise. After lh, the solution was concentrated under reduced pressure. The waxy solid residue was recrystallized from hexane, affording 0.81 g of the title compound, mp 78-79°C: *H NMR (400 MHz, CDCI3) δ 7.80 (m, 3H), 7.68 (s, IH), 7.47 (m, 2H), 7.31 (dd, J = 8.4 and 1.8 Hz, IH), 4.13 (s, 2H), 4.04 (s, 2H).
Step B. 2-(4-Bromophenyl)-4-(2-naphthylmethyl)thiazole. A solution of 0.50 g of 4-bromothiobenzamide (E. P. Papadopoulos, J. Or . Chem. 1976, 41, 962) and 0.44 g of 2-naphthylmethyl chloromethyl ketone obtained above in 10 mL of absolute ethanol was warmed at reflux for 18 h. The mixture was cooled in ice, and the solid was collected and washed with cold ethanol to afford 0.53 g of tan powder, mp 136-138°C: lH NMR (400 MHz, CDCI3) δ 7.85 (d, J = 8.6 Hz, 2H), 7.74-7.84 (m, 4H), 7.67 (d, J = 8.6 Hz, 2H), 7.44 (m, 3H), 7.28 (s, IH), 4.40 (s, 2H).
Step C. 4-[4-(2-Naphthylmethyl)thiazol-2-yl1benzenesulfonyl chloride. A solution of the above aryl bromide (0.53 g) in 10 mL of dry tetrahydrofuran was cooled to -78°C, and a solution of n-butyllithium (1.0 mL of 1.6 M in hexanes) was added dropwise. After 30 min, a steady stream of sulfur dioxide was introduced into the surface of the deep brown-red solution for a period of 5 min. The resulting yellow solution was stirred at -78°C for 10 min, and was then allowed to warm to room temperature. After 1 h, the mixture was concentrated under reduced pressure, and the residue was stirred with 20 mL of a 1:1 mixture of ether:hexane. The supernatant was decanted off, and the resulting off- white powder was dried under reduced pressure, and was subsequently suspended in 10 mL of dichloromethane and cooled in an ice-bath. N- chlorosuccinimide (0.175 g) was added in one portion, and the mixture was stirred at 0°C for 15 min. The cooling bath was removed and, after 30 min, the mixture was diluted with dichloromethane and filtered through a short pad of Celite. The residue obtained after evaporation was purified by flash chromatography on a silica gel column (8% ethyl acetate/hexane), affording 0.042 g of the title compound as an off-white solid: lH NMR (400 MHz, CDCI3) δ 7.93 (d, J = 8.5 Hz, 2H), 7.70-7.85 (m, 4H), 7.67 (d, J = 8.5 Hz, 2H), 7.40 (m, 3H), 7.26 (s, IH), 4.43 (s, 2H).
S tep D . (R N- \4- \2- \ f2-H ydrox y-2- (p y ridin-3 - vDeth yll aminol eth ll phenyll-4-[4-(2-naphthylmethyl thiazol-2-yl]benzenesulfonamide. A solution of 0.035 g of (R)-N-[2-[4-(aminophenyl)]ethyl]-2-hydroxy-2- (pyrid-3-yl)ethylcarbamic acid 1,1-dimethylethyl ester (Fisher, et. al, US 5,561,142, Oct. 1, 1996) in 1.5 mL of dichloromethane was treated with the above sulfonyl chloride (0.042 g) and pyridine (0.015 mL). The solution was stirred at 25°C for 18 h, and trifluoroacetic acid (3 mL) was added. After stirring for 1.5 h, the solution was concentrated under reduced pressure. Azeotropic distillation with methanol (10 mL) left an orange, viscous oil, which was purified by flash chromatography on silica gel (9: 1 dichloromethane: 10% ammonium hydroxide/methanol eluant) to afford 0.083- g of the title compound as a yellow foam. H NMR (400 MHz, CD3OD) δ 8.50 (d, J = 2.0 Hz, IH), 8.41 (dd, J = 4.9 and 1.6 Hz, IH), 7.83 (d, J = 8.0 Hz, 2H), 7.64-7.80 (m, 4H), 7.58 (s, IH), 7.3-7.5 (m, 7H), 7.04 (two overlapping d, J = 8.6 Hz, 4H), 4.79 (dd, J = 7.3 and 5.7 Hz, IH), 4.36 (s, 2H), 2.4-2.9 (m, 6H). FAB MS m z 621.
EXAMPLE 2
Figure imgf000037_0001
(R)-N-[4-[2-r[2-Hydroxy-2-(pyridin-3-yl ethyllaminolethyllphenyll-4-[4- (4-trifluoromethylphenyl thiazol-2-yl1benzenesulfonamide and salts
Step A. (R -N-[4-r2-[N-(l.l-Dimethylethoxycarbonyl -N-r2-hvdroxy-2- (pyridin-3-yl ethyl]amino1ethyl]phenyl]-4-aminothiocarbonyl benzene sulfonamide. A steady stream of hydrogen sulfide was bubbled into a solution of 10.2 g of (R)-N-[4-[2-[N-(l,l-dimethylethoxycarbonyl)-N-[2- hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-cyanobenzene- sulfonamide (Fisher, et. al, US 5,561,142, Oct. 1, 1996) and triethylamine (2.9 mL) in 100 mL of pyridine at 25 °C for 15 min. The green solution was stirred for 2.5 h, and then nitrogen was bubbled through the solution for 30 min. The reaction mixture was concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel (8% methanol in dichloromethane eluant), affording 9.31 g of title compound as a bright yellow foam. XH NMR (400 MHz, CD3OD) δ 8.45 (m, 2H), 7.87 (d, J = 8.5 Hz, 2H), 7.80 (m, IH), 7.70 (m, 2H), 7.01 (overlapping s, 4H and m, IH), 4.84 (m, IH), 3.15-3.45 (m, 4H), 2.7 (m, 2H), 1.30 (s, 9H).
Step B. (R -N-r4-r2-r[2-Hvdroxy-2-(pyridin-3-yl ethvnaminolethyll phenyl1-4-r4-(4-trifluoromethylphenyl)thiazol-2-yl1benzenesulfonamide. A mixture of 1.77 g of thioamide from step A above and 1.02 g of 4- (trifluoromethyl)phenyl chloromethylketone (synthesized from 4- (trifluoromethyl)benzoyl chloride and diazomethane as described in Example 1, Step A) in absolute ethanol (10 mL) was warmed at reflux for 18h. The cooled reaction mixture was concentrated under reduced pressure, and the residue was dissolved in 8 mL of dichloromethane and 2 mL of trifluoroacetic acid (TFA). After stirring for lh at ambient temperature, the solution was concentrated under reduced pressure. Residual TFA was removed by azeotropic distillation with dichloromethane, and the residue was purified by flash chromatography (9: 1 dichloromethane/ 10% NH4OH in methanol eluant), affording the title compound (1.36 g) as a white powder. XH NMR (400 MHz, CD3OD) δ 8.49 (d, J = 2.1 Hz, IH), 8.40 (dd, J = 5.0 and 1.5 Hz, IH), 8.18 (d, J = 7.9 Hz, 2H), 8.12 (d, J = 8.6 Hz, 2H), 8.09 (s, IH), 7.82 (d, J - 8.6 Hz, 2H), 7.77 (m, IH), 7.71 (d, J = 8.6 Hz, 2H), 7.35 (dd, J = 7.9 and 5.0 Hz, IH), 7.09 (d, J = 8.6 Hz, 2H), 7.04 (d, J = 8.6 Hz, 2H), ), 4.80 (dd, J = 7.3 and 5.7 Hz, IH), 2.70-2.90 (m, 6H). FAB MS m/z 625.
Dihydrochloride salt of title compound The free base from step B above (2.50 g) was briefly stirred with a methanolic solution of hydrochloric acid (prepared by addition of 0.64 mL of acetyl chloride to 10 mL of methanol at 0 °C for 15 min). Concentration under reduced pressure and drying in vacuo left 2.81 g of a light yellow powder, which was dissolved in 35 mL of absolute ethanol, filtered, seeded and allowed to slowly evaporate at ambient temperature. The resulting crystalline solid was collected, washed with cold ethanol, and dried in vacuo to afford the title compound (2.60 g), mp 215-218 °C. IH NMR (400 MHz, CD3OD) δ 8.96 (s, IH), 8.82 (d, J = 5.8 Hz, IH ), 8.68 (d, J = 8.2 Hz, IH), 8.20 (d, J = 8.2 Hz, 2H), 8.14 (d, J = 8.6 Hz, 2H), 8.13 (s, IH), 8.08 (dd, J = 8.0 and 5.7 Hz, IH), 7.87 (d, J = 8.6 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H), 5.3.0 (dd, J = 10.0 and 2.9 Hz, IH), 3.44 (dd, J = 12.7 and 2.9 Hz, IH), 3.20-3.35 (m, 4H), 2.97 (t, J = 8.3 Hz, 2H). FAB MS m/z 625 (M+l).
Dihydrobromide salt of title compound
The free base in methanol was treated with 2.2 equivalents of methanolic hydrogen bromide solution, stirred for 30 min at room temperature, filtered, and the filtrate concentrated and dried under reduced pressure. The residual powder was suspended in 2-propanol and warmed at reflux for 18 h. The solution was cooled slowly to room temperature with stirring, and was subsequently cooled in an ice-water bath. The pale yellow, crystalline powder was collected, washed with cold 2-propanol and dried in vacuo to afford the title compound, mp 199- 202 °C. IH NMR (400 MHz, CD3OD) d 8.97 (s, IH), 8.82 (d, J = 5.4 Hz, IH), 8.68 (d, J = 8.2 Hz, IH), 8.20 (d, J = 8.0 Hz, 2H), 8.14 (d, J = 8.6 Hz, 2H),.8.13 (s, IH), 8.08 (dd, J - 8.0 and 5.7 Hz, IH), 7.86 (d, J = 8.6 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H), 5.31 (dd, J = 10.0 and 3.1 Hz, IH), 3.44 (dd, J = 12.8 and 3.1 Hz, IH), 3.20-3.35 (m, 4H), 2.98 (t, J = 8.3 Hz, 2H).
Dimaleate salt of title compound
The free base was suspended in 2-propanol and treated with 2.0 equivalents of maleic acid. The suspension was warmed at reflux until all solids were dissolved, filtered-, allowed to cool slightly, seeded and then allowed to stand at room temperature overnight. The precipitated solid was collected, washed with 2-propanol, and dried in vacuo to afford the title compound as an off-white, crystalline powder, mp 154-156 °C. IH NMR (400 MHz, CD3OD) d 8.60 (d, J = 2.4 Hz,
IH), 8.51 (dd, J = 4.9 and 1.6 Hz, IH), 8.20 (d, J = 7.9 Hz, 2H), 8.14 (d, J = 8.5 Hz, 2H), 8.13 (s, IH), 7.93 (m, IH), 7.86 (d, J = 8.6 Hz, 2H), 7.49 (dd, J = 7.8 and 4.7 Hz, IH), 7.17 (d, J = 8.6 Hz, 2H), 7.12 (d, J = 8.6 Hz, 2H), 6.27 (4 H, s, maleic acid), 5.02 (dd, J = 10.1 and 3.3 Hz, IH), 3.15- 3.35 (m, 4H), 2.95 (m, 2H).
EXAMPLE 3
Figure imgf000040_0001
(R -N-r4-[2-rr2-Hvdroxy-2-(pyridin-3-yl ethyl]aminolethyllphenyll-4-r2- (4-trifluoromethylphenyl)thiazol-5-yl]benzenesulfonamide
Step A. α-Amino-4-bromoacetophenone hydrochloride. The general procedure for the modified Delepine reaction (Goddard, C. J. J. Heterocyclic Chem. 1991, 28, 17) was used. A mixture of , 4- dibromacetophenone (2.78 g) and hexamethylenetetramine (1.47 g) in 40 mL of chloroform was stirred vigorously overnight. The precipitated solid was collected, washed with chloroform, dried in vacuo, and was then suspended in a mixture of 6 mL of concentrated hydrochloric acid and 30 mL of methanol and stirred overnight. The precipitated solid was collected, washed with methanol and dried in vacuo, affording 1.38 g of white powder, which was used without further purification.
Step B. α-Amino-4-bromoacetophenone 4-(Trifluoromethyl benzamide. A mixture of the above hydrochloride salt (1.38 g) and triethylamine (1.50 mL) in 40 mL of chloroform was cooled in an ice- water bath, and a solution of 4- (trifluoromethyl)benzoyl chloride (1.21 g) in 5 mL of chloroform was added dropwise. The mixture was stirred at 0°C for 1 h, diluted with 30 mL of chloroform and washed sequentially with water, 5% aqueous hydrochloric acid, saturated aqueous sodium bicarbonate and saturated brine. Drying and removal of solvent under reduced pressure afforded an off-white solid, which was triturated with ethyl acetate: hexane (6: 1), collected, and dried, affording 1.20 g of the title compound as a white solid: mp 173-174°C; lH NMR (400 MHz, CDCI3) δ 7.96 (d, J = 8.0 Hz, 2H), 7.87 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.0 Hz, 2H), 7.67 (d, J = 8.6 Hz, 2H), 4.92 (apparent d, J = 4.3 Hz, 2H); FAB MS m/z 387.4 (M+l).
Step C. 5-(4-Bromophenyl -2-(4-Trifluoromethylphenyl)thiazole. A mixture of the amide from Step B above (0.386 g) and Lawesson's reagent (0.410 g) in 6 mL of dry toluene was warmed at reflux for 1.5 h. The solution was cooled and applied directly to a silica gel column. Sequential elution with hexane and then 10% ethyl acetate:hexane provided 0.380 g of the title compound as a white solid: *H NMR (400 MHz, CDCI3) δ 8.05 (d, J = 8.5 Hz, 2H), 8.03 (s, IH), 7.69 (d, J = 8.5 Hz, 2H), 7.55 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H); FAB MS m/z 385.9 (M+l).
Step D. 5-(4-Chlorosulfonylphenyl)-2-(4-Trifluoromethylphenyl thiazole. A solution of the above aryl bromide (0.356 g) in 6 mL of dry THF was treated with n-butyllithium (0.63 mL of 1.6 M in hexanes), followed by sulfur dioxide and then N-chlorosuccinimide as described in Example 1 , Step C above. The crude sulfonyl chloride obtained (0.171 g) was used without further purification: IH NMR (400 MHz, CDCI3) δ 8.09 (d, J = 8.5 Hz, 2H), 8.05 (s, IH), 7.58 (m, 4H), 7.45 (d, J = 8.6 Hz, 2H).
Step E. (R -N-r4-r2-r[2-Hvdroxy-2-(p^ridin-3-yl ethyllaminolethyll phenyll-4-[2-(4-trifluoromethylphenyl)thiazol-5-yl1benzenesulfonamide A solution of 0.131 g of (R)-N-[2-[4-(aminophenyl)]ethyl]-2-hydroxy-2- (pyrid-3-yl)ethylcarbamic acid 1,1-dimethylethyl ester in 1.6 mL of dichloromethane was treated with the above sulfonyl chloride (0.171 g) and 0.040 mL of pyridine, followed by addition of trifluoroacetic acid, as described in Example 1, Step D. The crude product was purified by flash chromatography on silica gel (9: 1 dichloromethane: 10% NHzj.OH/MeOH eluant) to afford 0.227 g of the title compound as a light yellow foam: lH NMR (400 MHz, CD3OD) δ 8.50 (d, J = 2.1 Hz, IH), 8.40 (dd, J = 5.0 and 1.6 Hz, IH), 8.27 (s, IH), 8.14 (d, J = 8.0 Hz, 2H), 7.79 (m, 7H), 7.09 (d, J = 8.6 Hz, 2H), 7.04 (d, J = 8.6 Hz, 2H), 4.78 (dd, J = 7.3 and 5.2 Hz, IH), 2.7-2.9 (m, 6H). FAB MS m/z 625.3 (M + 1).
EXAMPLE 4
Figure imgf000042_0001
(R -N-[4-[2-rr2-Hvdroxy-2-rpyridin-3-yDethyllaminolethyl1phenyll-4-[4- (4-trifluoromethoxyphenyl thiazol-2-yl]benzenesulfonamide
The title compound was prepared according to the procedure outlined in Example 2: lH NMR (400 MHz, CD OD) δ 8.52 (d, J = 2.0 Hz, IH), 8.43 (dd, J = 4.9 and 1.6 Hz, IH), 8.12 (d, J = 8.5 Hz, 2H), 8.10 (d, J = 8.6 Hz, 2H), 7.98 (s, IH), 7.83 (overlapping d, J = 8.5 Hz, 2H and m, IH), 7.38 ( dd, J = 7.9 and 5.0 Hz, IH), 7.33 (d, J = 8.6 Hz, 2H), 7.12 (d, J = 8.5 Hz, 2H), 7.07 (d, J = 8.5 Hz, 2H), 4.85 (dd, J = 8.8 and 4.2 Hz, IH), 2.7-3.1 (m, 6H). FAB MS m z 641 (M+l).
Following the procedures outlined for Examples 1 and 2, the compounds listed in Table 1 were prepared.
TABLE 1
Figure imgf000043_0001
Figure imgf000043_0002
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
EXAMPLE 39
Figure imgf000047_0002
(R)-N-r4-r2-[[2-Hvdroxy-2-(pyridin-3-vnethyllaminolethyllphenvn-4-r5- (4-fluorophenyl thiazol-2-yl]benzenesulfonamide Step A. 2-Bromo-2-(4-fluorophenyl)ethanal. To a solution of 672 mg of o-iodoxybenzoic acid in methyl sulfoxide (5 mL) was added 250 μL of 2- (4-fluorophenyl)ethanol and stirring was continued for 3h. Water (20 mL) was added and the reaction mixture filtered, the filtrate was extracted with ether (3 x 20 mL), washed with brine (10 mL), dried over masgnesium sulfate, and concentrated to give 2-(4-fluorophenyl) ethanal as an unstable oil. The material was immediately dissolved in acetonitrile (3.5 mL) at 0°C and 264 μL of bromotrimethylsilane and 142 μL of methyl sulfoxide were added. After stirring for lh, water (10 mL) was added and the reaction mixture was extracted with ether (3 x 20 mL), washed with brine (10 mL), dried over magnesium sulfate, and concentrated to give the title compound (220 mg) as an unstable oil which was used immediately without further purification.
Step B (R -N-[4-r2-r[2-Hvdroxy-2-(pyridin-3-yDethyllaminolethyll phenyll-4-[5-(4-fluorophenyl)thiazol-2-ynbenzenesulfonamide. A mixture of 50 mg of thioamide from Example 2, step A and 220 mg of 2- bromo-2-(4-fluorophenyl)ethanal in chloroform acetonitrile (2/1 1.5 mL) was warmed at reflux for 16h. The cooled reaction mixture was concentrated under reduced pressure and purified by preparative thin layer chromatography (9: 1 dichloromethane/ methanol eluant) to give (R)-N- [4- [2- [ - ( 1 , 1 -dimethylethoxycarbonyl)-N- [2-hydroxy-2-(pyridin- 3-yl)ethyl]amino]ethyl]phenyl]-4-[5-(4-fluorophenyl)thiazol-2- yl]benzenesulfonamide (12 mg). This was dissolved in 2 mL of dichloromethane and 2 mL of triffuoroacetic acid (TFA). After stirring for 2h at ambient temperature, the solution was concentrated under reduced pressure. Residual TFA was removed by azeotropic distillation with dichloromethane, and the residue was purified by preparative thin layer chromatography (9: 1 dichloromethane/10% NH4OH in methanol eluant) and then preparative reverse phase HPLC (65/35 methanol/10% TFA in water eluant) affording the title compound (5.0 mg). ^H NMR (400 MHz, CD3OD) δ 8.75 (m, IH), 8.66 (m, IH), 8.13 (s, IH), 8.06 (d, J = 8 Hz, 2H), 7.85 (d, J = 8 Hz, 2H), 7.79-7.69 (m, 3H), 7.22-7.09 (m, 6H), 5.16-5.10 (m, IH), 3.30-3.17 (m, 4H), 2.98-2.91 (m, 2H).
EXAMPLE 40
Figure imgf000049_0001
f RVN- \ - \2- r [2-Hvdroxy-2-(pyridin-3-y Dethyll aminolethyllphenyll -4- r2- (4-trifluoromethylphenyl thiazol-4-ynbenzenesulfonamide
Step A. 4-(Trifluoromethyl )thiobenzamide. 4-(Trifluoromethyl)benzonitrile (3.42 g) was treated with triethylamine (2.12 g) and hydrogen sulfide in pyridine solution as described in Example 2, Step A. The crude product was triturated with hexane (150 mL) and collected to afford 3.80 g of yellow powder: mp 133-136°C; lH NMR (400 MHz, CDCI3) δ 7.92 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H).
Step B. 4-(4-Bromophenyl)-2-(4-Trifluoromethylphenyl thiazole. A solution of the above thioamide (0.41 g) and α,4-dibromoacetophenone (0.56 g) in 5 mL of absolute ethanol was warmed at reflux for 14 h. The reaction mixture was cooled in ice, and the solid was collected and washed with ethanol, affording 0.67 g of a white, crystalline solid: mp 143-144°C; *H NMR (400 MHz, CDCI3) δ 8.12 (d, J = 7.9 Hz, 2H), 7.85 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 7.9 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.53 (s, IH); FAB MS m/z 386.1 (M+l).
Step C. 4-f4-Bromophenyl)-2-(4-Trifluoromethylphenyl)-5- ftrimethylsilyPthiazole. A solution of the aryl bromide obtained above (0.576 g) in 10 mL of dry tetrahydrofuran (THF) was cooled in a dry ice-acetone bath, and a solution of n-butyllithium (1.0 mL of 1.6 M in hexanes) was added dropwise. After an additional 10 min, trimethylsilyl chloride (0.196 g, 0.23 mL) was added in one portion. After an additional 15 min, the cooling bath was removed, and the reaction mixture was allowed to warm to room temperature over 1 h. Saturated aqueous ammonium chloride (1 mL) was added, and the mixture was concentrated under reduced pressure. Ether-water partition-washing afforded a white, waxy solid, which was purified by flash chromatography on a silica gel column (5% ethyl acetate-hexane eluant) to provide 0.49 g of the title compound as a white solid: mp 88-89°C; }H NMR (400 MHz, CDCI3) δ 8.09 (d, J = 8.1 Hz, 2H), 7.67 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 8.6 Hz, 2H), 0.25 (s, 9H); FAB MS m/z 458.0 (M+l).
Step D. 4-f4-Chlorosulfonylphenyl -2-(4-Trifluoromethylphenyl)-5- (trimethy lsily Dthiazole . The aryl bromide from above (0.456 g) was treated with n-butyllithium, followed by sulfur dioxide and then N-chlorosuccinimide as described in Example 1, Step C above. The crude product (0.223 g) was used without further purification.
Step E. (RVN-r4-r2-rr2-Hvdroxy-2-(pyridin-3-yl ethyllaminolethyllphenyn-4- [2-(,4-trifluoromethylphenyl)thiazol-4-yllbenzenesulfonamide. A solution of 0.150 g of (R)-N-[2-[4-(aminophenyl)]ethyl]-2-hydroxy-2-(pyrid-3- yl)ethylcarbamic acid 1,1-dimethylethyl ester (Fisher, et. al , US 5,561,142, Oct. 1, 1996) in 1.6 mL of dichloromethane was treated with the above sulfonyl chloride (0.223 g) and 0.040 mL of pyridine, followed by addition of trifluoroacetic acid, as described in Example 1, Step D. The crude product was purified by flash chromatography on silica gel (9: 1 dichloromethane: 10% ammonium hydroxide/methanol eluant) to afford 0.171 g of a light yellow foam, which was dissolved in 2 mL of acetonitrile and treated with a 15% solution of HF in acetonitrile. The mixture was stirred at room temperature for 1.5 h, and was then concentrated under reduced pressure. The crude product was purified by flash chromatography on a silica gel column (9:1 dichloromethane: 10% ammonium hydroxide/methanol eluant) to afford 0.091 g of the title compound as a light yellow foam: *H NMR (400 MHz, CD3OD) δ 8.49 (d, J = 2.1 Hz, IH), 8.40 (dd, J = 4.9 and 1.6 Hz, IH), 8.19 (d, J = 7.7 Hz, 2H), 8.11 (d, J = 8.6 Hz, 2H), 8.05 (s, IH), 7.78 (apparent t, J = 8.5 Hz, 4H), 7.35 (dd, J = 5.0 and 7.9, IH), 7.09 (d, J = 8.6 Hz, 2H), 7.04 (d, J = 8.6 Hz, 2H), 4.77 (dd, J = 7.4 and 5.2 Hz, IH), 2.7-2.9 (m, 6H); FAB MS m/z 625.3 (M + 1).
EXAMPLE 41
Figure imgf000051_0001
(RVN- [4- 2- [ r2-H vdroxy-2-(py ridin-3- vDethyll aminolethyllphenyll -4- \2- (4-trifluoromethoxyphenyl thiazol-4-ynbenzenesulfonamide
The title compound was prepared according to the procedure outlined in
Example 40: IH NMR (400 MHz, CD3OD) δ 8.50 (d, J = 2.1 Hz, IH), 8.40 (dd, J = 4.9 and 1.6 Hz, IH), 8.11 (d, J = 2.9 Hz, 2H), 8.09 (d, J = 2.9 Hz, 2H), 7.99 (s, IH), 7.78 (apparent d, J = 8.7 Hz, 3H), 7.37 (apparent d, J = 8.7 Hz, 2H), 7.35 (m, IH), 7.09 (d, J = 8.7 Hz, 2H), 7.04 (d, J = 8.7 Hz, 2H), 4.76 (dd, J = 7.4 and 5.1 Hz, IH), 2.7-2.9 (m, 6H); FAB MS m/z 641.3 (M + 1).

Claims

WHAT IS CLAIMED IS:
A compound having the formula I:
Figure imgf000052_0001
wherein
X is (1) a bond,
(2) C1-C3 alkylene, optionally substituted with 1 or 2 groups selected from methyl and halogen,
(3) C1-C3 alkylene wherein said alkylene contains an oxygen, optionally substituted with 1 or 2 groups selected from methyl and halogen;
Figure imgf000052_0002
A is (1) phenyl,
(2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(3) a benzene ring fused to a C5-C10 carbocyclic ring,
(4) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or
(5) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5-C10 carbocyclic ring;
Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy,
(b) halogen, (c) cyano,
(d) QR2,
(e) C3-C8 cycloalkyi,
(f) A optionally substituted with up to 5 groups selected from halogen, Cl-ClO alkyl and Cl-ClO alkoxy,
(g) Q'COR3,
(h) S(0)nR3, where n is 0 to 2,
(i) NR2S╬╕2R3,
(j) NR2C02R2, and
(k) C02R2,
(2) C3-C8 cycloalkyi,
(3) oxo,
(4) halogen,
(5) cyano,
(6) QR2,
(7) S(0)nR3, where n is 0 to 2,
(8) Q'COR3,
(9) NR2S02R3,
(10) NR2C02R2,
(11) A optionally substituted with up to 5 groups independently selected from
(a) R2,
(b) QR2,
(c) halogen, and
(d) oxo; or
(12) C02R2;
R2 is (1) hydrogen,
(2) Cl-ClO alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy,
(b) halogen,
(c) CO2R4,
(d) S(O)n-Cl-CK) alkyl, where n is 0 to 2,
(e) C3-C8 cycloalkyi, (f) Cl-ClO alkoxy, and
(g) A optionally substituted with up to 5 groups selected from halogen, Cl-ClO alkyl and Cl-ClO alkoxy, (3) C3-C8 cycloalkyi, or (4) A optionally substituted with up to 5 groups selected from
(a) halogen,
(b) nitro,
(c) oxo, (d) NR4R4,
(e) Cl-ClO alkoxy,
(f) S(O)n-Cl-Cl0 alkyl where n is 0 to 2, and
(g) Cl-ClO alkyl optionally substituted with up to 5 groups selected from hydroxy, halogen, CO2R4, S(0)n-Cl-Cl╬╕ alkyl, where n is 0 to 2, C3-C8 cycloalkyi, Cl-ClO alkoxy, and A optionally substituted with up to 5 groups selected from halogen, Cl-ClO alkyl and Cl-ClO alkoxy; R3 is (1) R2 or (2) NR2R2;
R4 is (1) H, or
(2) Cl-ClO alkyl; Q is (1) N(R2),
(2) O or (3) S(0)n, and n is 0 to 2;
Q' is (1) N(R2),
(2) O or
(3) a bond; or a pharmaceutically acceptable salt thereof or a prodrug thereof.
2. A compound of Claim 1 wherein X is (1) a bond,
(2) CH2, (3) CH2O, wherein C is attached to thiazole, and O is attached to A.
3. A compound of Claim 1 wherein
Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 haloj *ens;
(2) halogen,
(3) QR2,
(4) Q'COR3,
(5) phenyl;
R2 is (1) hydrogen,
(2) Cl-ClO alkyl optionally substituted with up to 5 haloj ^ens;
R3 is (1) Cl-C 10 alkyl; and
Q is (1) 0.
4. A compound of Claim 1 wherein X is (1) a bond,
(2) CH2, (3) CH2O, wherein C is attached to thiazole, and O is attached to A; m is 0 to 5;
A is (1) phenyl,
(2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(3) a benzene ring fused to a C5-C10 carbocyclic ring,
(4) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or
(5) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5-C10 carbocyclic ring; Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 haloj *ens;
(2) halogen,
(3) QR2,
(4) Q'COR3,
(5) phenyl;
R is (1) hydrogen,
(2) Cl-ClO alkyl optionally substituted with up to 5 halo^ *ens;
R3 is (1) Cl-ClO alkyl; and
Q is (1) O.
5. A compound of Claim 1 wherein either the benzenesulfonamide moiety or X (or A, if X is a bond) is attached to the C2 of the thiazole ring, and the other to the C4 positions of the thiazole ring.
6. A compound of Claim 5 wherein X is (1) a bond, (2) CH2,
(3) CH2O, wherein C is attached to thiazole, and O is attached to A; m is 0 to 5;
A is (1) phenyl, (2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(3) naphthyl, or
(4) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a benzene ring;
Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 halogens;
(2) halogen,
(3) QR2, (4) Q'COR3,
(5) phenyl; R2 is (1) hydrogen,
(2) Cl-C 10 alkyl optionally substituted with up to 5 halogens;
R3 is (1) Cl-ClO alkyl; and
Q is (1) O.
7. A compound of Claim 6 wherein A is selected from the group consisting of phenyl, naphthyl, thienyl, pyridinyl, benzothienyl, quinolinyl, indolyl, and benzofuranyl.
8. A compound selected from the group consisting of: N- [4- [2- [ [2-hy droxy-2-(3-pyridinyl)ethyl] amino] ethy l]phenyl] -4- [4-(2- naphthylmethyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4- (trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4- (trifluoromethoxy )pheny 1] thiazol-2-yl]benzenesulf onamide ; N- [4- [2- [ [2-hy droxy-2- (py ridin-3 -y l)ethyl] amino] ethyl] phenyl] -4- [4- (3,4-difluorophenylmethyl)thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3- pyridyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4- fluorophenylmethyl)thiazol-2-yl]benzenesulf onamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3,4-difluorophenyl)thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4- (trifluoromethyl)phenylmethyl]thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(2- pyridyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[l- (2-phenyl)ethyl]thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4- fluorophenyl)thiazol-2-yl]benzenesulfonamide;
N- [4- [2- [ [2-hydroxy-2- (pyridin- 3 -y l)ethyl] amino] ethyljpheny 1] -4- [4- (2- naphthyl)thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3,4,5-trifluorophenyl)thiazol-2-yl]benzenesulfonamide;
N- [4- [2- [ [2-hy droxy-2- (py ridin- 3-y l)ethy 1] amino] ethyl]pheny 1] -4- [4-(4- hexylphenyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4- (trifluoromethoxy)phenylmethyl]thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4- (trifluoromethoxy)phenoxymethyl]thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(2- benzo[b]thienyl)thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3- quinolinyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(6- quinolinyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(2- benzo[b]furyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3- indolyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (2,4-difluorophenyl)thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3,5-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
N- [4- [2- [[2-hydroxy-2-(pyridin-3-yl)ethyl] amino]ethyl]phenyl] -4- [4- [4- (1,1 -dimethylethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (2,3-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(ρyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[3- (trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
N- [4- [2- [ [2-hy droxy-2- (pyridin- 3 -y l)ethy 1] amino] ethy l]pheny 1] -4- [4- [4- (difluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (2,4-dichlorophenyl)thiazol-2-yl]benzenesulfonamide;
N- [4- [2- [ [2-hydroxy-2-(pyridin-3-yl)ethyl] amino] ethyl]phenyl]-4- [4- [2- (trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[2- fluoro-4-(trif uoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
N- [4- [2- [ [2-hydroxy-2-(pyridin-3-yl)ethyl] amino] ethyl]phenyl]-4- [4- [4- fluoro-2-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- [2,4-bis(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[5-(4- fluorophenyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[2-(4- trifluoromethylphenyl)thiazol-4-yl]benzenesulfonamide; N- [4- [2- [ [2-Hydroxy-2-(pyridin-3-yl)ethyl] amino] ethyl]phenyl] -4- [2-(4- trifluoromethylphenyl)thiazol-5-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4- phenylphenyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4- (3,4-dihydroxyphenyl)thiazol-2-yl]benzenesulfonamide;
N- [4- [2- [ [2-hy droxy-2-(py ridin-3 -y l)ethy 1] amino] ethyl] phenyl] -4- [4- (4- hydroxyphenyl)thiazol-2-yl]benzenesulfonamide;
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4- acetoxyphenyl)thiazol-2-yl]benzenesulfonamide; N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4- acetamidophenyl)thiazol-2-yl]benzenesulfonamide; and
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[2-(4- trifluoromethoxyphenyl)thiazol-4-yl]benzenesulfonamide.
9. A compound of Claim 1 having the formula:
Figure imgf000060_0001
10. A method for the treatment of diabetes which comprises administering to a diabetic patient an effective amount of a compound of Claim 1.
.11. A method for the treatment of obesity in a mammal which comprises administering to mammal an effective amount of a compound of Claim 1.
12. A method for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels which comprises administering to a patient needing lower triglyceride and cholesterol levels or higher high density lipoprotein levels an effective amount of a compound of Claim 1.
13. A method for decreasing gut motility which comprises administering to a patient in need of decreased gut motility, an effective amount of a compound of Claim 1.
14. A method for reducing neurogenic inflammation of airways which comprises administering to a patient in need of reduced neurogenic inflammation, an effective amount of a compound of Claim 1.
15. A method for reducing depression which comprises administering to a depressed patient an effective amount of a compound of Claim 1.
16. A method for treating gastrointestinal disorders which comprises administering to a patient with gastrointestinal disorders an effective amount of a compound of Claim 1.
17. A composition for the treatment of diabetes or obesity or for lowering triglyceride or cholesterol levels or increasing high density lipoprotein levels or for decreasing gut motility or for reducing neurogenic inflammation or for treating depression or for treating gastrointestinal disorders which comprises an inert carrier and an effective amount of a compound of Claim 1.
18. A pharmaceutical composition which comprises a compound of formula I and a pharmaceutically acceptable carrier.
PCT/US1998/001317 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY WO1998032753A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU60384/98A AU728812B2 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
HU0002053A HUP0002053A3 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
EEP199900328A EE9900328A (en) 1997-01-28 1998-01-23 Thiazole Benzenesulfonamides as β3-Agonists in the Treatment of Diabetes and Obesity
JP53214898A JP2001509166A (en) 1997-01-28 1998-01-23 Thiazolebenzenesulfonamide as a beta lower agonist for the treatment of diabetes and obesity
IL13113098A IL131130A0 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
PL98334833A PL334833A1 (en) 1997-01-28 1998-01-23 Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity
EA199900692A EA199900692A1 (en) 1997-01-28 1998-01-23 BENZOLSULFAMIDA THIAZOLE AS β-AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
EP98903677A EP0968209A1 (en) 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES AS $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
CA002278739A CA2278739A1 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as .beta.3 agonists for the treatment of diabetes and obesity
BR9807096-7A BR9807096A (en) 1997-01-28 1998-01-23 Compound, processes for the treatment of diabetes, obesity in a mammal, to reduce levels of triglycerides and cholesterol levels or to raise levels of high density lipoproteins, to decrease motility of the intestine, to reduce neurogenic inflammation of the airways and depression and to treat gastrointestinal disorders, and, compositions for the treatment of the above and pharmaceutical disorders
SK1000-99A SK100099A3 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as 'beta'3 agonists for the treatment of diabetes and obesity
IS5131A IS5131A (en) 1997-01-28 1999-07-23 Thiazole benzenesulfonamide as a β3 agonist for the treatment of diabetes and obesity
NO993646A NO993646L (en) 1997-01-28 1999-07-27 Thiazolebenzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity
BG103686A BG103686A (en) 1997-01-28 1999-08-24 Thiazole benzenesulphonamides as beta 3-agonists for the treatment of diabetes and obesity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28
US60/036,760 1997-01-28
GBGB9705041.3A GB9705041D0 (en) 1997-03-12 1997-03-12 Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity
GB9705041.3 1997-03-12

Publications (1)

Publication Number Publication Date
WO1998032753A1 true WO1998032753A1 (en) 1998-07-30

Family

ID=26311166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/001317 WO1998032753A1 (en) 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Country Status (22)

Country Link
EP (1) EP0968209A1 (en)
JP (1) JP2001509166A (en)
KR (1) KR20000070568A (en)
CN (1) CN1251099A (en)
AR (1) AR011092A1 (en)
AU (1) AU728812B2 (en)
BG (1) BG103686A (en)
BR (1) BR9807096A (en)
CA (1) CA2278739A1 (en)
EA (1) EA199900692A1 (en)
EE (1) EE9900328A (en)
HR (1) HRP980044A2 (en)
HU (1) HUP0002053A3 (en)
ID (1) ID22273A (en)
IL (1) IL131130A0 (en)
IS (1) IS5131A (en)
NO (1) NO993646L (en)
PE (1) PE52299A1 (en)
PL (1) PL334833A1 (en)
SK (1) SK100099A3 (en)
TR (1) TR199902442T2 (en)
WO (1) WO1998032753A1 (en)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062892A1 (en) * 1998-05-29 1999-12-09 Novartis Ag Aminoazole compounds
WO2001054728A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
EP1138685A2 (en) * 2000-03-31 2001-10-04 Pfizer Products Inc. Process for preparing substituted pyridines
WO2002006276A1 (en) * 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
WO2002006221A2 (en) * 2000-07-17 2002-01-24 Wyeth Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
WO2002014312A1 (en) * 2000-08-15 2002-02-21 F. Hoffmann-La Roche Ag Tetrazolyl-phenyl acetamide glucokinase activators
WO2002046186A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
WO2003000687A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
WO2003037332A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
US6569873B2 (en) 2000-07-17 2003-05-27 Wyeth Azolidines as beta-3 adrenergic receptor agonists
US6583140B2 (en) 2000-07-17 2003-06-24 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6660752B2 (en) 2001-04-23 2003-12-09 Bayer Pharmaceuticals Corporation 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
US6699860B2 (en) 2000-12-11 2004-03-02 Bayer Pharmaceuticals Corporation Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US7022716B2 (en) 2000-07-17 2006-04-04 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
WO2006132196A1 (en) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST
EP1741446A2 (en) 2000-01-21 2007-01-10 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2007033266A2 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
WO2007044296A3 (en) * 2005-10-04 2007-09-27 Merck & Co Inc Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2014033343A1 (en) 2012-08-29 2014-03-06 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US10288602B2 (en) 2013-01-08 2019-05-14 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatement
US11357757B2 (en) 2017-09-13 2022-06-14 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11427539B2 (en) 2017-09-13 2022-08-30 Atrogi Ab Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US11648216B2 (en) 2017-09-13 2023-05-16 Atrogi Ab Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
US11793774B2 (en) 2017-09-13 2023-10-24 Atrogi Ab Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
WO2023203223A1 (en) 2022-04-22 2023-10-26 Atrogi Ab Combinations of beta 2-adrenergic receptor agonists and beta 3-adrenergic receptor agonists, and medical uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A2 (en) * 1982-04-08 1983-10-19 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
EP0611003A1 (en) * 1993-02-09 1994-08-17 Merck & Co. Inc. Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
WO1995029159A1 (en) * 1994-04-26 1995-11-02 Merck & Co., Inc. SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A2 (en) * 1982-04-08 1983-10-19 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
EP0611003A1 (en) * 1993-02-09 1994-08-17 Merck & Co. Inc. Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
WO1995029159A1 (en) * 1994-04-26 1995-11-02 Merck & Co., Inc. SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062892A1 (en) * 1998-05-29 1999-12-09 Novartis Ag Aminoazole compounds
EP1743655A1 (en) 2000-01-21 2007-01-17 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
EP1741446A2 (en) 2000-01-21 2007-01-10 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2001054728A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
EP1138685A3 (en) * 2000-03-31 2003-04-02 Pfizer Products Inc. Process for preparing substituted pyridines
EP1138685A2 (en) * 2000-03-31 2001-10-04 Pfizer Products Inc. Process for preparing substituted pyridines
US6670480B2 (en) 2000-03-31 2003-12-30 Pfizer Inc. Process for preparing substituted pyridines
US6518431B2 (en) 2000-03-31 2003-02-11 Pfizer Inc. Process for preparing substituted pyridines
US6844441B2 (en) 2000-03-31 2005-01-18 Pfizer Inc Process for preparing substituted pyridines
WO2002006276A1 (en) * 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
US6730792B2 (en) 2000-07-13 2004-05-04 Eli Lilly And Company β3 adrenergic agonists
US6649603B2 (en) 2000-07-17 2003-11-18 Wyeth Cyclylamine sulfonamides as β3-adrenergic receptor agonists
US6569873B2 (en) 2000-07-17 2003-05-27 Wyeth Azolidines as beta-3 adrenergic receptor agonists
US6583140B2 (en) 2000-07-17 2003-06-24 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
WO2002006221A3 (en) * 2000-07-17 2002-06-13 American Home Prod Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
US7022716B2 (en) 2000-07-17 2006-04-04 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2002006221A2 (en) * 2000-07-17 2002-01-24 Wyeth Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
US6821991B2 (en) 2000-07-17 2004-11-23 Wyeth 2-substituted thiazolidinones as β-3 adrenergic receptor agonists
WO2002014312A1 (en) * 2000-08-15 2002-02-21 F. Hoffmann-La Roche Ag Tetrazolyl-phenyl acetamide glucokinase activators
US7122680B2 (en) 2000-11-10 2006-10-17 Eli Lilly And Company 3-Substituted oxindole β3 agonsists
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
WO2002046186A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
US7067537B2 (en) 2000-12-08 2006-06-27 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
US6699860B2 (en) 2000-12-11 2004-03-02 Bayer Pharmaceuticals Corporation Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
US6660752B2 (en) 2001-04-23 2003-12-09 Bayer Pharmaceuticals Corporation 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
US6919371B2 (en) 2001-04-23 2005-07-19 Bayer Pharmaceuticals Corporation 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
WO2003000687A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
US7087635B2 (en) 2001-08-14 2006-08-08 Eli Lilly And Company 3-substituted oxindole β3 agonists
WO2003037332A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
US7253181B2 (en) 2001-11-20 2007-08-07 Eli Lilly And Company β3 adrenergic agonists
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
US7265127B2 (en) 2001-11-20 2007-09-04 Eli Lilly And Company β3 adrenergic agonists
US7241772B2 (en) 2001-11-20 2007-07-10 Eli Lilly And Company β3 adrenergic agonists
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US7214697B2 (en) 2002-01-11 2007-05-08 Eli Lilly And Company 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2006132196A1 (en) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST
WO2007033266A2 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007044296A3 (en) * 2005-10-04 2007-09-27 Merck & Co Inc Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
US7893091B2 (en) 2005-10-04 2011-02-22 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014033343A1 (en) 2012-08-29 2014-03-06 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
US10288602B2 (en) 2013-01-08 2019-05-14 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatement
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US11357757B2 (en) 2017-09-13 2022-06-14 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11793774B2 (en) 2017-09-13 2023-10-24 Atrogi Ab Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
US11648216B2 (en) 2017-09-13 2023-05-16 Atrogi Ab Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
US12036210B2 (en) 2017-09-13 2024-07-16 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11427539B2 (en) 2017-09-13 2022-08-30 Atrogi Ab Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
WO2023203223A1 (en) 2022-04-22 2023-10-26 Atrogi Ab Combinations of beta 2-adrenergic receptor agonists and beta 3-adrenergic receptor agonists, and medical uses thereof

Also Published As

Publication number Publication date
EE9900328A (en) 2000-02-15
CN1251099A (en) 2000-04-19
AR011092A1 (en) 2000-08-02
EA199900692A1 (en) 2000-02-28
AU6038498A (en) 1998-08-18
BG103686A (en) 2000-06-30
PE52299A1 (en) 1999-05-26
IS5131A (en) 1999-07-23
KR20000070568A (en) 2000-11-25
HUP0002053A2 (en) 2001-08-28
IL131130A0 (en) 2001-01-28
BR9807096A (en) 2000-04-18
HUP0002053A3 (en) 2001-09-28
NO993646D0 (en) 1999-07-27
ID22273A (en) 1999-09-23
EP0968209A1 (en) 2000-01-05
TR199902442T2 (en) 2000-07-21
JP2001509166A (en) 2001-07-10
SK100099A3 (en) 2000-05-16
NO993646L (en) 1999-09-27
CA2278739A1 (en) 1998-07-30
AU728812B2 (en) 2001-01-18
PL334833A1 (en) 2000-03-27
HRP980044A2 (en) 1998-10-31

Similar Documents

Publication Publication Date Title
AU728812B2 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
US6011048A (en) Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
AU712057B2 (en) Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
US6291491B1 (en) Amide derivatives as β 3 agonists
US5451677A (en) Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5705515A (en) Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
AU717699B2 (en) Chemical compounds
JP3149186B2 (en) Substituted sulfonamides as selective beta-3 agents for the treatment of diabetes and obesity
JP5290749B2 (en) Activator of peroxisome proliferator activated receptor δ
US5541197A (en) Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
RU2501794C2 (en) Activating agent for receptor activated by peroxisome growth-stimulating agents
AU4689500A (en) Di-aryl acid derivatives as ppar receptor ligands
WO2009083526A1 (en) Novel compounds
JPWO2002046176A1 (en) Activator of peroxisome proliferator-activated receptor
JP2010532748A (en) 2-Substituted indole derivatives as calcium channel blockers
JP2002506033A (en) Vitronectin receptor antagonist
JP4986927B2 (en) Medicine
US6034106A (en) Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
US7638540B2 (en) Benzofuran compound and medicinal composition containing the same
CA2521135A1 (en) N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
JP6937524B2 (en) Amide compounds and their use
US20080207685A1 (en) Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
CZ268199A3 (en) Thiazole benzenesulfonamides and pharmaceutical preparation containing thereof
MXPA99007032A (en) THIAZOLE BENZENESULFONAMIDES AS&amp;bgr;3
US20060217375A1 (en) New compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131130

Country of ref document: IL

Ref document number: 98803585.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1998 532148

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09341943

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 100099

Country of ref document: SK

Ref document number: 336891

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2278739

Country of ref document: CA

Ref document number: 2278739

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998903677

Country of ref document: EP

Ref document number: P-348/99

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: PV1999-2681

Country of ref document: CZ

Ref document number: PA/a/1999/007032

Country of ref document: MX

Ref document number: 1019997006814

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 60384/98

Country of ref document: AU

Ref document number: 199900692

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1999/02442

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1998903677

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-2681

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1999-2681

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997006814

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 60384/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998903677

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997006814

Country of ref document: KR